Antigen binding protein constructs and uses thereof

Abstract

Provided herein are antigen binding protein constructs capable of specifically binding MET or epitopes of MET presented on the surface of a target mammalian cell, wherein the antigen binding is pH dependent. Uses of the antigen binding protein constructs are also provided.

Description

[0001] This application is a divisional application of the Chinese invention patent application with the application date of July 30, 2020, application number 202080066488.1, and invention name “Antigen-binding protein constructs and their uses”. Technical Field

[0002] The present disclosure relates to the field of biotechnology, and more particularly to antigen binding molecules. Background Art

[0003] Antibody-drug conjugates have been designed to combat a variety of diseases. A particular advantage of this approach is that antibody-drug conjugates can have cytostatic or cytotoxic effects. Despite years of development, there is a need for improved antibody-drug conjugates. Summary of the Invention

[0004] The present invention is based on the concept that antigen binding protein constructs can be generated that exhibit enhanced efficacy (e.g., one or more of: increased toxin release in target mammalian cells (e.g., a detectable increase), increased killing of target mammalian cells (e.g., a detectable increase), and increased endolysosomal delivery (e.g., a detectable increase)).

[0005] Provided herein are pharmaceutical compositions comprising an effective amount of an antigen binding protein construct (ABPC) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell, wherein: (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0; or (b) the first antigen binding domain has a dissociation constant (K) at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0. D ) than K at a pH of about 7.0 to about 8.0 D big.

[0006] In some embodiments of any of the pharmaceutical compositions described herein, the ABPC is degraded in the target mammalian cell after the ABPC is internalized by the target mammalian cell.

[0007] In some embodiments of any of the pharmaceutical compositions described herein, the ABPC comprises a conjugated toxin, radioisotope, drug, or small molecule.

[0008] Also provided herein are pharmaceutical compositions comprising an effective amount of an antigen binding protein construct (ABPC) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell; and a conjugated toxin, radioisotope, drug, or small molecule, wherein (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0 or the dissociation constant (K) of the first antigen binding domain at a pH of about 4.0 to about 6.5 is greater than that at a pH of about 7.0 to about 8.0. D ) than K at a pH of about 7.0 to about 8.0 D and (b) the composition provides one or more of: an increase in toxin release in the target mammalian cells compared to a composition comprising the same amount of a control ABPC; an increase in target mammalian cell killing compared to a composition comprising the same amount of a control ABPC; and an increase in endolysosomal delivery in the target mammalian cells compared to a composition comprising the same amount of a control ABPC.

[0009] In some embodiments of any of the pharmaceutical compositions described herein, the first antigen-binding domain comprises one of (a) to (c): (a) a heavy chain variable domain of telisotuzumab having one or more amino acids substituted with histidine, wherein the heavy chain variable domain of telisotuzumab comprises SEQ ID NO: 1; and / or a light chain variable domain of telisotuzumab having one or more amino acids substituted with histidine, wherein the light chain variable domain of telisotuzumab comprises SEQ ID NO: 2; (b) a heavy chain variable domain of emibetuzumab having one or more amino acids substituted with histidine, wherein the heavy chain variable domain of emibetuzumab comprises SEQ ID NO: 146; and / or a light chain variable domain of emibetuzumab having one or more amino acids substituted with histidine, wherein the light chain variable domain of emibetuzumab comprises SEQ ID NO: NO: 147; (c) a heavy chain variable domain of hucMET27Gv1.3 in which one or more amino acids are substituted by histidine, wherein the heavy chain variable domain of hucMET27Gv1.3 comprises SEQ ID NO: 304; and / or a light chain variable domain of hucMET27Gv1.3 in which one or more amino acids are substituted by histidine, wherein the light chain variable domain of hucMET27Gv1.3 comprises SEQ ID NO: 305; (d) a heavy chain variable domain of P3D12 in which one or more amino acids are substituted by histidine, wherein the heavy chain variable domain of P3D12 comprises SEQ ID NO: 502; and / or a light chain variable domain of P3D12 in which one or more amino acids are substituted by histidine, wherein the light chain variable domain of P3D12 comprises SEQ ID NO: 503.

[0010] In some embodiments of any of the pharmaceutical compositions described herein, the first MET-binding domain comprises one of (a) to (d): (a) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 3-5, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 3-5 are substituted with histidine; and / or a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 6-8, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 6-8 are substituted with histidine; (b) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 148-150, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 148-150 are substituted with histidine; and / or a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 151-153, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 151-153 are substituted with histidine; (c) a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 151-153, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: and (d) a heavy chain variable domain comprising CDR1s, CDR2s, and CDR3s of SEQ ID NOs: 504-506, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 504-506 have been substituted with histidine; and / or a light chain variable domain comprising CDR1s, CDR2s, and CDR3s of SEQ ID NOs: 507-509, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 507-509 have been substituted with histidine.

[0011] In some embodiments of any of the pharmaceutical compositions described herein, the first antigen binding domain comprises one of (a) to (d): (a) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO: 1; and / or a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO: 2; (b) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, NO: 146 at one or more histidine positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103; and / or a light chain variable domain at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 of SEQ ID NO: 147; (c) a heavy chain variable domain at least 90% identical to SEQ ID NO: 304, wherein the heavy chain variable domain includes a NO: 304 at one or more histidine positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and / or a light chain variable domain at least 90% identical to SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 of SEQ ID NO: 305; and (d) a heavy chain variable domain at least 90% identical to SEQ ID NO: 502, wherein the heavy chain variable domain includes ID NO: 502 at one or more positions of histidine selected from the group consisting of 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107;and / or a light chain variable domain that is at least 90% identical to SEQ ID NO: 503, wherein the light chain variable domain comprises a histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 of SEQ ID NO: 503;

[0012] In some embodiments of any of the pharmaceutical compositions described herein, the first antigen binding domain comprises one of (a) to (d): (a) SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140. NO: 140, and / or a heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94 or SEQ ID NO: 111, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain that is not SEQ ID NO: NO: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94 and 111; or (iii) the heavy chain variable domain of SEQ ID NO: 1 and the light chain variable domain that is not one of SEQ ID NO: 52, 55-59, 61-67, 71, 72, 75, 79, 81 and 131-140; (b) SEQ ID NO: 147,The light chain variable domain of SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300 or SEQ ID NO: 301, and / or the heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235 or SEQ ID NO: 236wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228, and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a light chain variable domain that is not one of SEQ ID NOs: 190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300, and 301; (c) SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358 ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492,The light chain variable domain of SEQ ID NO: 494, SEQ ID NO: 496 or SEQ ID NO: 499, and / or the heavy chain variable domain of SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399 or SEQ ID NO: 400wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain that is not one of SEQ ID NOs: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a heavy chain variable domain that is not one of SEQ ID NOs: : and (d) a light chain variable domain of one of SEQ ID NOs: 352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496, and 499; and (d) a light chain variable domain of one of SEQ ID NOs: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:705, SEQ ID NO:706, SEQ ID NO:707, SEQ ID NO:708, SEQ ID NO:709, SEQ ID NO:710, SEQ ID NO:711, SEQ ID NO:712, SEQ ID NO:713 or SEQ ID The light chain variable domain of NO:732, and / or SEQ ID NO:502, SEQ ID NO:511, SEQ ID NO:513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519,SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659 or SEQ ID NO: 676, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain that is not one of SEQ ID NOs: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659 and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and a heavy chain variable domain that is not one of SEQ ID NOs: A light chain variable domain of one of NOs: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713, and 732.

[0013] In some embodiments of any of the pharmaceutical compositions described herein, the composition provides: an increase in toxin release from the target mammalian cells compared to a composition comprising the same amount of a control ABPC; and / or an increase in target mammalian cell killing compared to a composition comprising the same amount of a control ABPC.

[0014] In some embodiments of any of the pharmaceutical compositions described herein, the composition provides increased endolysosomal delivery in the target mammalian cell compared to a composition comprising the same amount of a control ABPC.

[0015] In some embodiments of any of the pharmaceutical compositions described herein, the composition causes less of a decrease in the level of MET presented on the surface of a target mammalian cell; or causes no detectable decrease in the level of MET presented on the surface of a target mammalian cell, compared to a composition comprising the same amount of a control ABPC.

[0016] In some embodiments of any of the pharmaceutical compositions described herein, the target mammalian cell is a cancer cell.

[0017] In some embodiments of any of the pharmaceutical compositions described herein, the ABPCs are cytotoxic or cytostatic to target mammalian cells. In some embodiments of any of the pharmaceutical compositions described herein, the ABPCs are cross-reactive with non-human primate MET and human MET, or with one or both of non-human primate MET, human MET, and rat MET and mouse MET.

[0018] In some embodiments of any of the pharmaceutical compositions described herein, the ABPC comprises a single polypeptide. In some embodiments of any of the pharmaceutical compositions described herein, the antigen binding domain is selected from the group consisting of a VH domain, a VHH domain, a VNAR domain, and a scFv. In some embodiments of any of the pharmaceutical compositions described herein, the ABPC comprises two or more polypeptides. In some embodiments of any of the pharmaceutical compositions described herein, the ABPC is an antibody.

[0019] In some embodiments of any of the pharmaceutical compositions described herein, the half-life of the ABPC in vivo is reduced compared to the half-life of a control ABPC in vivo.

[0020] In some embodiments of any of the pharmaceutical compositions described herein, the ABPC comprises a second antigen binding domain.

[0021] Also provided herein are antigen binding protein constructs (ABPCs) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell, wherein: (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0; and / or (b) the first antigen binding domain has a dissociation constant (K) at a pH of about 4.0 to about 6.5. D) than K at a pH of about 7.0 to about 8.0 D big.

[0022] In some embodiments of any of the ABPCs described herein, the ABPC is degraded in the target mammalian cell after the ABPC is internalized by the target mammalian cell.

[0023] In some embodiments of any of the ABPCs described herein, the ABPC comprises a conjugated toxin, radioisotope, drug, or small molecule.

[0024] Also provided herein are antigen binding protein constructs (ABPCs) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell; and a conjugated toxin, radioisotope, drug, or small molecule, wherein (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0 or the dissociation constant (K) of the first antigen binding domain at a pH of about 4.0 to about 6.5 is greater than that at a pH of about 7.0 to about 8.0. D ) than K at a pH of about 7.0 to about 8.0 D and (b) the composition provides one or more of: an increase in toxin release in the target mammalian cells compared to a composition comprising the same amount of a control ABPC; an increase in target mammalian cell killing compared to a composition comprising the same amount of a control ABPC; and an increase in endolysosomal delivery in the target mammalian cells compared to a composition comprising the same amount of a control ABPC.

[0025] In some embodiments of any of the ABPCs described herein, the first antigen-binding domain comprises one of (a) to (c): (a) a heavy chain variable domain of terituzumab having one or more amino acids substituted with histidine, wherein the heavy chain variable domain of terituzumab comprises SEQ ID NO: 1; and / or a light chain variable domain of terituzumab having one or more amino acids substituted with histidine, wherein the light chain variable domain of terituzumab comprises SEQ ID NO: 2; (b) a heavy chain variable domain of imatuzumab having one or more amino acids substituted with histidine, wherein the heavy chain variable domain of imatuzumab comprises SEQ ID NO: 146; and / or a light chain variable domain of imatuzumab having one or more amino acids substituted with histidine, wherein the light chain variable domain of imatuzumab comprises SEQ ID NO: NO: 147; (c) a heavy chain variable domain of hucMET27Gv1.3 in which one or more amino acids are substituted by histidine, wherein the heavy chain variable domain of hucMET27Gv1.3 comprises SEQ ID NO: 304; and / or a light chain variable domain of hucMET27Gv1.3 in which one or more amino acids are substituted by histidine, wherein the light chain variable domain of hucMET27Gv1.3 comprises SEQ ID NO: 305; (d) a heavy chain variable domain of P3D12 in which one or more amino acids are substituted by histidine, wherein the heavy chain variable domain of P3D12 comprises SEQ ID NO: 502; and / or a light chain variable domain of P3D12 in which one or more amino acids are substituted by histidine, wherein the light chain variable domain of P3D12 comprises SEQ ID NO: 503.

[0026] In some embodiments of any ABPC described herein, the first MET binding domain comprises one of (a) to (d): (a) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 3-5, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 3-5 are substituted with histidine; and / or a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 6-8, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 6-8 are substituted with histidine; (b) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 148-150, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 148-150 are substituted with histidine; and / or a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 151-153, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 151-153 are substituted with histidine; (c) a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 151-153, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: and (d) a heavy chain variable domain comprising CDR1s, CDR2s, and CDR3s of SEQ ID NOs: 504-506, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 504-506 have been substituted with histidine; and / or a light chain variable domain comprising CDR1s, CDR2s, and CDR3s of SEQ ID NOs: 507-509, respectively, wherein a total of one or more amino acid positions in SEQ ID NOs: 507-509 have been substituted with histidine.

[0027] In some embodiments of any of the ABPCs described herein, the first antigen binding domain comprises one of (a) to (d): (a) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 1, wherein the heavy chain variable domain comprises a histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO: 1; and / or a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain comprises a histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO: 2; (b) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises a histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, NO: 146 at one or more histidine positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103; and / or a light chain variable domain at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 of SEQ ID NO: 147; (c) a heavy chain variable domain at least 90% identical to SEQ ID NO: 304, wherein the heavy chain variable domain includes a NO: 304 at one or more histidine positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and / or a light chain variable domain at least 90% identical to SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 of SEQ ID NO: 305; and (d) a heavy chain variable domain at least 90% identical to SEQ ID NO: 502, wherein the heavy chain variable domain includes NO: 502 at one or more histidine positions selected from the group consisting of 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107;and / or a light chain variable domain that is at least 90% identical to SEQ ID NO: 503, wherein the light chain variable domain comprises a histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 of SEQ ID NO: 503;

[0028] In some embodiments of any of the ABPCs described herein, the first antigen binding domain comprises one of (a) to (d): (a) SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140. NO: 140, a light chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94 or SEQ ID NO: 111, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain that is not SEQ ID NO: NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140;(b) The light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300 or SEQ ID NO: 301, and / or the light chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230,;

[0029] The heavy chain variable domain of SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235 or SEQ ID NO: 236, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228 and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a heavy chain variable domain that is not one of SEQ ID NOs: : (c) SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435 NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474,SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID NO: 496 or the light chain variable domain of SEQ ID NO: 499, and / or SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399 or SEQ ID NO: 400, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain that is not SEQ ID NO: NO: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a heavy chain variable domain that is not SEQ ID NO: 352, 356, 357, 360,

[0030] A light chain variable domain of one of 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428 - 446, 450, 451, 453, 457, 462, 463, 465, 470, 472 - 474, 476, 479, 482, 483, 485, 490, 492, 494, 496 and 499; and (d) a light chain variable domain of SEQ ID NO: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 7 / 12, SEQ ID NO: 713 or SEQ ID NO: 732, and / or SEQ ID NO: 502, SEQ ID NO: 511, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581,SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659 or SEQ ID NO: 676, wherein the first antigen binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain that is not SEQ ID NO: NO: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659 and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and a light chain variable domain that is not one of SEQ ID NO: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713 and 732.

[0031] In some embodiments of any ABPC described herein, a composition comprising the ABPC provides: an increase in toxin release from the target mammalian cells compared to a composition comprising the same amount of a control ABPC; and / or an increase in target mammalian cell killing compared to a composition comprising the same amount of a control ABPC.

[0032] In some embodiments of any of the ABPCs described herein, a composition comprising the ABPC provides increased endolysosomal delivery in the target mammalian cell compared to a composition comprising the same amount of a control ABPC.

[0033] In some embodiments of any of the ABPCs described herein, a composition comprising the ABPCs causes less of a decrease in the level of MET presented on the surface of a target mammalian cell than a composition comprising the same amount of a control ABPC; or causes no detectable decrease in the level of MET presented on the surface of a target mammalian cell.

[0034] In some embodiments of any of the ABPCs described herein, the target mammalian cell is a cancer cell. In some embodiments of any of the ABPCs described herein, the ABPC is cytotoxic or cytostatic to the target mammalian cell. In some embodiments of any of the ABPCs described herein, the ABPC is cross-reactive with non-human primate MET and human MET, or with one or both of non-human primate MET, human MET, and rat MET and mouse MET.

[0035] In some embodiments of any ABPC described herein, the ABPC comprises a single polypeptide. In some embodiments of any ABPC described herein, the antigen binding domain is selected from the group consisting of: a VH domain, a VHH domain, a VNAR domain, and a scFv. In some embodiments of any ABPC described herein, the ABPC comprises two or more polypeptides. In some embodiments of any ABPC described herein, the ABPC is an antibody.

[0036] In some embodiments of any of the ABPCs described herein, the half-life of the ABPC in vivo is reduced compared to the half-life of a control ABPC in vivo.

[0037] In some embodiments of any of the ABPCs described herein, the ABPC comprises a second antigen binding domain.

[0038] Also provided herein are kits comprising at least one dose of any one of the pharmaceutical compositions described herein or any one of the ABPCs described herein.

[0039] Also provided herein are methods of treating cancer characterized by a population of cancer cells having MET or an epitope of MET presented on their surface, the method comprising administering a therapeutically effective amount of any one of the pharmaceutical compositions described herein or any one of the ABPCs described herein to a subject identified as having a cancer characterized by having said population of cancer cells.

[0040] Also provided herein are methods of reducing the volume of a tumor in a subject, wherein the tumor is characterized by a population of cancer cells having MET or an epitope of MET presented on its surface, the method comprising administering a therapeutically effective amount of any pharmaceutical composition described herein or any ABPC described herein to a subject identified as having a cancer characterized by the population of cancer cells.

[0041] Also provided herein are methods of inducing cell death in cancer cells in a subject, wherein the cancer cells have MET or an epitope of MET presented on their surface, wherein the method comprises administering a therapeutically effective amount of any one of the pharmaceutical compositions described herein or any one of the ABPCs described herein to a subject identified as having a cancer characterized by having a population of said cancer cells.

[0042] Also provided herein are methods of reducing the risk of developing metastasis or reducing the risk of developing additional metastases in a subject having cancer, wherein the cancer is characterized by a population of cancer cells having MET or an epitope of MET presented on its surface, the method comprising administering a therapeutically effective amount of any one of the pharmaceutical compositions described herein or any one of the ABPCs described herein to a subject identified as having cancer characterized by the population of cancer cells.

[0043] As used herein, the term "antigen-binding protein construct" is (i) a single polypeptide comprising at least one antigen-binding domain or (ii) a complex of two or more polypeptides (e.g., the same polypeptide or different polypeptides) that together form at least one antigen-binding domain. Non-limiting examples and aspects of antigen-binding protein constructs are described herein. Additional examples and aspects of antigen-binding protein constructs are known in the art.

[0044] "Multispecific antigen-binding protein construct" is an antigen-binding protein construct comprising two or more different antigen-binding domains that specifically bind to two or more different epitopes. The two or more different epitopes can be epitopes on the same antigen (e.g., a single polypeptide present on a cell surface) or different antigens (e.g., present on the same cell surface or on different cell surfaces). In some aspects, antigens are present on the cell surface. In some aspects, the multispecific antigen-binding protein construct binds to two different epitopes (i.e., a "bispecific antigen-binding protein construct"). In some aspects, the multispecific antigen-binding protein construct binds to three different epitopes (i.e., a "trispecific antigen-binding protein construct"). In some aspects, the multispecific antigen-binding protein construct binds to four different epitopes (i.e., a "tetraspecific antigen-binding protein construct"). In some aspects, the multispecific antigen-binding protein construct binds to five different epitopes (i.e., a "pentaspecific antigen-binding protein construct"). Each binding specificity can exist with any suitable valence. Non-limiting examples of multispecific antigen-binding protein constructs are described herein.

[0045] "Antigen binding domain" is one or more protein domains (e.g., formed by amino acids from a single polypeptide or by amino acids from two or more polypeptides (e.g., the same polypeptide or different polypeptides)) that can specifically bind to one or more different antigens. In some examples, the antigen binding domain can bind to an antigen or epitope with a specificity and affinity similar to that of a naturally occurring antibody. In some embodiments, the antigen binding domain can be an antibody or fragment thereof. In some embodiments, the antigen binding domain can include an alternative scaffold. Non-limiting examples of antigen binding domains are described herein. Additional examples of antigen binding domains are known in the art. In some examples, the antigen binding domain can bind to a single antigen.

[0046] The term "antibody" is used herein in its broadest sense and includes certain types of immunoglobulin molecules that include one or more antigen binding domains that specifically bind to an antigen or epitope. Antibodies particularly include, for example, complete antibodies (e.g., complete immunoglobulins, such as human IgG (e.g., human IgG1, human IgG2, human IgG3, human IgG4)), antibody fragments, and multispecific antibodies. An example of an antigen binding domain is an antigen binding domain formed by a VH-VL dimer. Additional examples of antibodies are described herein. Additional examples of antibodies are known in the art.

[0047] The phrase "endosomal / lysosomal pathway" refers to the network of endosomes (early endosomes, multivesicular bodies, late endosomes, and lysosomes) in the cytoplasm of mammalian cells where molecules internalized by cell-mediated internalization processes (e.g., pinocytosis, micropinocytosis, receptor-mediated endocytosis, and / or phagocytosis) are sorted.

[0048] Once the endosomes in the endosomal / lysosomal pathway are purified or isolated, the target protein (e.g., an antigen binding protein construct described herein) can be assayed using methods known in the art (ELISA, Western blot, immunofluorescence, and immunoprecipitation followed by determination of protein concentration) and can be used to determine the concentration or relative level of the target protein in the endosome. Alternatively, immunofluorescence microscopy can be used using a detectably labeled antibody (e.g., a fluorophore-labeled antibody, a dye-labeled antibody, or a GFP-labeled antibody, e.g., CellLight TM Endosomes in the endosomal / lysosomal pathway can be imaged by combining a fluorescently labeled early endosome-GFP) and a fluorophore-labeled antibody that specifically binds to a protein of interest (e.g., an antigen binding protein construct), and the level of the target protein in the endosome can be determined by quantifying the overlap in the fluorescence emission of the two different antibodies.

[0049] The phrase "endolysosomal delivery" refers to the rate of accumulation of an antigen binding protein construct (e.g., any antigen binding protein construct described herein) in the endosomal / lysosomal pathway of a mammalian cell (e.g., any exemplary target mammalian cell described herein) over time or the total rate of accumulation at a particular time point.

[0050] An exemplary method for calculating the increase in endosomal delivery of a pH-engineered ABPC variant compared to its corresponding starting ABPC from cellular fluorescence data is to measure the mean fluorescence intensity of the variant minus the mean fluorescence intensity of a non-binding IgG control and then divide the whole by the ratio of the mean fluorescence intensity of the variant's corresponding starting ABPC minus the mean fluorescence intensity of the IgG control.

[0051] Exemplary assays for measuring endosomal delivery of any ABPC described herein include those involving labeling the ABPC with a fluorescent dye, followed by incubation of the labeled ABPC with cells and measuring cell fluorescence as an indicator of ABPC endolysosomal delivery (e.g., as generally described in Wustner, Traffic 7(6): 699-715, 2006). Alternatively, a pH-sensitive dye that preferentially fluoresces at acidic pH rather than neutral pH can be used to label any ABPC described herein, which can then be incubated with cells and cell fluorescence measured as an indicator of ABPC delivery to the acidic endolysosomal compartment.

[0052] The term "population" when used before a noun means two or more of the specific noun. For example, the phrase "cancer cell population" means "two or more cancer cells." Non-limiting examples of cancer cells are described herein.

[0053] The phrase "cytostatic to cells" refers to a direct or indirect reduction in the proliferation (cell division) of cells (e.g., cancer cells) in vivo or in vitro. When an agent is cytostatic to cells, the agent can, for example, directly or indirectly cause cell cycle arrest of cells (e.g., cancer cells). In some instances, an agent that is cytostatic to cells can reduce the number of cells in S phase in a cell population (compared to the number of cells in S phase in the cell population prior to contact with the agent). In some instances, an agent that is cytostatic to cells can reduce the percentage of cells in S phase by at least 20%, at least 40%, at least 60%, or at least 80% (e.g., compared to the percentage of cells in S phase in the cell population prior to contact with the agent).

[0054] The phrase "cytotoxic to cells" refers to inducing, directly or indirectly, cell death (eg, necrosis or apoptosis) of cells (eg, mammalian cells, such as cancer cells).

[0055] "Affinity" refers to the total strength of non-covalent interactions between an antigen binding site and its binding partner (e.g., an antigen or epitope). Unless otherwise indicated, as used herein, "affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between an antigen binding domain and an antigen or epitope. The affinity of a molecule X for its partner Y can be expressed in terms of the dissociation equilibrium constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be measured, for example, using surface plasmon resonance (SPR) technology (e.g., ) or biofilm interference techniques (e.g. Additional methods for determining the affinity of an antigen binding domain for its corresponding antigen or epitope are known in the art.

[0056] The term "epitope" means a portion of an antigen that is specifically bound by an antigen binding domain through a set of physical interactions between: (i) all monomers on the portion of the antigen binding domain that specifically binds to the antigen (e.g., individual amino acid residues, sugar side chains, and post-translationally modified amino acid residues), and (ii) all monomers on the portion of the antigen that is specifically bound by the antigen binding domain (e.g., individual amino acid residues, sugar side chains, and post-translationally modified amino acid residues). An epitope can, for example, consist of surface-accessible amino acid residues, sugar side chains, phosphorylated amino acid residues, methylated amino acid residues, and / or acetylated amino acid residues and can have specific three-dimensional structural characteristics and specific charge characteristics. The difference between a conformational epitope and a non-conformational epitope is that binding to the former, rather than binding to the latter, may be lost in the presence of a denaturing solvent. In some embodiments, an epitope is defined by a linear amino acid sequence of at least about 3 to 6 amino acids or about 10 to 15 amino acids. In some embodiments, an epitope refers to a portion of a full-length protein defined by a three-dimensional structure (e.g., protein folding) or a portion thereof. In some embodiments, an epitope is defined by a discontinuous amino acid sequence that is aggregated via protein folding. In some embodiments, an epitope is defined by a discontinuous amino acid sequence held together by a quaternary structure (e.g., a cleft formed by the interaction of two different polypeptide chains). The amino acid sequence between the residues defining the epitope may not be critical to the three-dimensional structure of the epitope. Conformational epitopes can be determined and screened using assays that compare binding of antigen-binding protein constructs to denatured forms of the antigen in order to generate linear epitopes. An epitope can include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding.

[0057] Methods for identifying the epitope to which an antigen binding domain specifically binds are known in the art, such as structure-based analysis (e.g., X-ray crystallography, NMR and / or electron microscopy) (e.g., based on the antigen and / or antigen-antigen binding domain complex) and / or mutagenesis-based analysis (e.g., alanine scanning mutagenesis, glycine scanning mutagenesis, and homology scanning mutagenesis), wherein mutants are measured in binding assays with a binding partner, many of which are known in the art.

[0058] The term "paratope" means a portion of an antigen-binding domain that specifically binds to an antigen through a set of physical interactions between: (i) all monomers on the portion of the antigen-binding domain that specifically binds to the antigen (e.g., individual amino acid residues, sugar side chains, post-translationally modified amino acid residues), and (ii) all monomers on the portion of the antigen that is specifically bound by the antigen-binding domain (e.g., individual amino acid residues, sugar side chains, post-translationally modified amino acid residues). A paratope can, for example, consist of surface-accessible amino acid residues and can have specific three-dimensional structural characteristics and specific charge characteristics. In some embodiments, a paratope refers to a portion or a portion of a full-length antigen-binding domain defined by a three-dimensional structure (e.g., a protein fold). In some embodiments, a paratope is defined by a discontinuous amino acid sequence that is brought together via protein folding. In some embodiments, an epitope is defined by a discontinuous amino acid sequence that is brought together by a quaternary structure (e.g., a cleft formed by the interaction of two different polypeptide chains). The amino acid sequence between the residues that define the paratope may not be critical to the three-dimensional structure of the paratope. A paratope may include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding.

[0059] Methods for identifying the paratope to which an antigen binding domain specifically binds are known in the art, such as structure-based analysis (e.g., X-ray crystallography, NMR and / or electron microscopy) (e.g., based on the antigen binding domain, and / or antigen binding domain-antigen complex), and / or mutagenesis-based analysis (e.g., alanine scanning mutagenesis, glycine scanning mutagenesis, and homology scanning mutagenesis), wherein mutants are measured in binding assays with a binding partner, many of which are known in the art.

[0060] The phrase "present on the surface of a mammalian cell" means an antigen that is (1) physically attached to or at least partially embedded in the plasma membrane of a mammalian cell (e.g., a transmembrane protein, a peripheral membrane protein, a lipid-anchored protein (e.g., a GPI-anchor), an N-myristoylated protein, or an S-palmitoylated protein) or (2) stably bound to its cognate receptor, wherein the cognate receptor is physically attached to the plasma membrane of a mammalian cell (e.g., a ligand that binds to its cognate receptor, wherein the cognate receptor is physically attached to the plasma membrane). Non-limiting methods for determining the presence of an antigen on the surface of a mammalian cell include fluorescence activated cell sorting (FACS), immunohistochemistry, cell fractionation assays, and Western blotting.

[0061] The phrase "control ABPC" or "control antigen-binding protein construct" means (i) an ABPC capable of specifically binding to MET or an epitope of MET presented on the surface of a mammalian cell (e.g., a target mammalian cell), wherein one or both of the following are true: (a) the off-rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 (e.g., any subrange of this range described herein) is no more than 3 times (e.g., no more than 2.8 times) faster than the off-rate at a pH of about 7.0 to about 8.0 (e.g., any subrange of this range described herein); , no more than 2.6-fold, no more than 2.5-fold, no more than 2.4-fold, no more than 2.2-fold, no more than 2.0-fold, no more than 1.8-fold, no more than 1.6-fold, no more than 1.5-fold, no more than 1.4-fold, no more than 1.2-fold, no more than 1.0-fold, no more than 0.8-fold, no more than 0.6-fold, no more than 0.5-fold, no more than 0.4-fold, no more than 0.3-fold, no more than 0.2-fold, or no more than 0.1-fold); or (b) the dissociation constant (K) of the first antigen binding domain at a pH of about 4.0 to about 6.5 (e.g., any subrange of this range described herein). D ) than the K at a pH (e.g., any subrange of this range described herein) of about 7.0 to about 8.0 (e.g., any subrange of this range described herein). D greater, no greater than 3 times (e.g., no greater than 2.8 times, no greater than 2.6 times, no greater than 2.5 times, no greater than 2.4 times, no greater than 2.2 times, no greater than 2.0 times, no greater than 1.8 times, no greater than 1.6 times, no greater than 1.5 times, no greater than 1.4 times, no greater than 1.2 times, no greater than 1.0 times, no greater than 0.8 times, no greater than 0.6 times, no greater than 0.5 times, no greater than 0.4 times, no greater than 0.3 times, no greater than 0.2 times, or no greater than 0.1 times); and / or (ii) terituzumab; and / or (iii) imatinib; and / or (iv) hucMET27Gv1.3; and / or (v) P3D12 (Tanabe).

[0062] The term "extracellular space" refers to the fluid outside the plasma membrane of a mammalian cell. When the mammalian cell is in vitro, the extracellular space can be a liquid culture medium. When the mammalian cell is in vivo, the extracellular space can be, for example, plasma, serum, blood, interstitial fluid, or lymph.

[0063] The term "endolysosomal space" refers to the fluid enclosed by the vesicles and organelles that constitute the endosomal / lysosomal pathway in mammalian cells.

[0064] The phrase "reduced levels" or "decreased levels" can be a decrease or decrease of at least 1% (e.g., at least 2%, at least 4%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, at least 20%, at least 22%, at least 24%, at least 26%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) compared to a reference level or reference value.

[0065] The term "cell killing efficacy" refers to the ability of an agent (e.g., any ABPC described herein) to directly or indirectly induce apoptosis and / or necrosis of mammalian cells (e.g., cancer cells) as measured over time or at a rate at a relevant time point. Methods for determining the cell killing efficacy of cells are known in the art (e.g., trypan blue staining, microscopy, fluorescence-assisted cell sorting, and assays for detecting apoptosis markers (e.g., annexin V). In a non-limiting example, the cell killing efficacy can be measured by, for example, by killing cells at a single concentration of the agent, by the IC50 of the agent (i.e., the concentration of the agent that achieves half the maximum cell killing efficacy), or by the ratio of the dissociation constant KD of the agent on mammalian cells divided by its IC50. In some non-limiting examples, the IC50 and / or KD ratios described herein are compared to those of a control ABPC (as defined herein), and it is optionally demonstrated that the ABPC described herein has a higher cell killing efficacy compared to the control ABPC.

[0066] The term "toxin release" refers to the ability of a mammalian cell (e.g., a non-cancerous mammalian cell or a cancer cell) to internalize (e.g., via pinocytosis and / or receptor-mediated endocytosis) any ABPC described herein (e.g., any ABPC described herein or a control AB) conjugated to a toxin, as measured over time or at a specific time point, and subsequently release the toxin conjugated to the ABPC. Toxin release can be assessed using a variety of different exemplary assays, such as ELISA, immunofluorescence, cell killing assays, cell cycle arrest assays, DNA damage assays, mass spectrometry, HPLC, and / or isotope-labeled toxins.

[0067] The phrase "target cell" or "target mammalian cell" or "mammalian target cell" means a mammalian cell having at least one MET present on its surface. In some examples, the mammalian target cell can be a cancer cell. In some embodiments of the target mammalian cell, there can be a total of about 1 to about 10,000,000, about 1 to about 9,000,000, about 1 to about 8,000,000, about 1 to about 7,000,000, about 1 to about 6,000,000, about 1 to about 5,000,000, about 1 to about 4,000,000, about 1 to about 3,000,000, about 1 to about 2,000,000, about 1 to about 1,000,000, about 1 to about 800,000, about 1 to about 600,000, about 1 to about 400,000, about 1 to about 200,000, about 1 to about 1 00,000, about 1 to about 80,000, about 1 to about 80,000, about 1 to about 75,000, about 1 to about 70,000, about 1 to about 65,000, about 1 to about 60,000, about 1 to about 55,000, about 1 to about 50,000, about 1 to about 45,000, about 1 to about 40,000, about 1 to about 35,000, about 1 to about 30,000, about 1 to about 25,000, about 1 to about 20,000, about 1 to about 15,000, about 1 to about 10,000, about 1 to about 7,500, about 1 to about 5,000, about 1 to about 4,000, about 1 to about 3,000, about 1 to about 2, 000, about 1 to about 1,000, about 1 to about 500, about 1 to about 100, about 1 to about 50, about 1 to about 10, about 10 to about 10,000,000, about 10 to about 9,000,000, about 10 to about 8,000,000, about 10 to about 7,000,000, about 10 to about 6,000,000, about 10 to about 5,000,000, about 10 to about 4,000,000, about 10 to about 3,000,000, about 10 to about 2,000,000, about 10 to about 1,000,000, about 10 to about 800,000, about 10 to about 600,000, about 10 to about 400 ,000, about 10 to about 200,000, about 10 to about 100,000, about 10 to about 80,000, about 10 to about 80,000, about 10 to about 75,000, about 10 to about 70,000, about 10 to about 65,000, about 10 to about 60,000, about 10 to about 55,000, about 10 to about 50,000, about 10 to about 45,000, about 10 to about 40,000, about 10 to about 35,000, about 10 to about 30,000, about 10 to about 25,000, about 10 to about 20,000, about 10 to about 15,000, about 10 to about 10,000, about 10 to about 7,00, about 50 to about 5,000, about 10 to about 4,000, about 10 to about 3,000, about 10 to about 2,000, about 10 to about 1,000, about 10 to about 500, about 10 to about 100, about 10 to about 50, about 50 to about 10,000,000, about 50 to about 9,000,000, about 50 to about 8,000,000, about 50 to about 7,000,000, about 50 to about 6,000,000, about 50 to about 5,000,000, about 50 to about 4,000,000, about 50 to about 3,000,000, about 50 to about 2,000,000, about 50 to about 1,000,000, about 50 to about 800,000, about 50 to about 600,000, about 50 to about 400,000, about 50 to about 200,000, about 50 to about 100,000, about 50 to about 80,000, about 50 to about 80,000, about 50 to about 75,000, about 50 to about 70,000, about 50 to about 65,000, about 50 to about 60,000, about 50 to about 55,000, about 50 to about 50,000, about 50 to about 45,000, about 50 to about 40,000, about 50 to about 35,000, about 50 to about 30,000, about 50 to about 25,000, about 50 to about 20,000, about 50 to about 15,000, about 50 to about 10,000, about 50 to about 7 ,500, about 50 to about 5,000, about 50 to about 4,000, about 50 to about 3,000, about 50 to about 2,000, about 50 to about 1,000, about 50 to about 500, about 50 to about 100, about 100 to about 10,000,000, about 100 to about 9,000,000, about 100 to about 8,000,000, about 100 to about 7,000,000, about 100 to about 6,000,000, about 100 to about 5,000,000, about 100 to about 4,000,000, about 100 to about 3,000,000, about 100 to about 2,000,000, about 100 to about 1,000,000, about 100 to about 800,0 00, about 100 to about 600,000, about 100 to about 400,000, about 100 to about 200,000, about 100 to about 100,000, about 100 to about 80,000, about 100 to about 75,000, about 100 to about 70,000, about 100 to about 65,000, about 100 to about 60,000, about 100 to about 55,000, about 100 to about 50,000, about 100 to about 45,000, about 100 to about 40,000, about 100 to about 35,000, about 100 to about 30,000, about 100 to about 25,000, about 100 to about 20,000, about 100 to about 15,000, about 100 to about 10,000, about 100 to about 7,500, about 100 to about 5,000, about 100 to about 4,000, about 100 to about 3,000, about 100 to about 2,000, about 100 to about 1,000, about 100 to about 500, about 500 to about 10,000,000, about 500 to about 9,000,000, about 500 to about 8,000,000, about 500 to about 7,000,000, about 500 to about 6,000,000, about 500 to about 5,000,000, about 500 to about 4,000,000, about 500 to about 3,000,000, about 500 to about 2,000,000, about 500 to about 1,000,000, about 5 00 to about 800,000, about 500 to about 600,000, about 500 to about 400,000, about 500 to about 200,000, about 500 to about 100,000, about 500 to about 80,000, about 500 to about 75,000, about 500 to about 70,000, about 500 to about 65,000, about 500 to about 60,000, about 500 to about 55,000, about 500 to about 50,000, about 500 to about 45,000, about 500 to about 40,000, about 500 to about 35,000, about 500 to about 30,000, about 500 to about 25,000, about 500 to about 20,000, about 500 to about 15,000, from about 500 to about 10,000, from about 500 to about 7,500, from about 500 to about 5,000, from about 500 to about 4,000, from about 500 to about 3,000, from about 500 to about 2,000, from about 500 to about 1,000, from about 1,000 to about 10,000,000, from about 1,000 to about 9,000,000, from about 1,000 to about 8,000,000, from about 1,000 to about 7,000,000, from about 1,000 to about 6,000,000, from about 1,000 to about 5,000,000, from about 1,000 to about 4,000,000, from about 1,000 to about 3,000,000, from about 1,000 to about 2,000,000, 1,000 to about 1,000,000, about 1,000 to about 800,000, about 1,000 to about 600,000, about 1,000 to about 400,000, about 1,000 to about 200,000, about 1,000 to about 100,000, about 1,000 to about 80,000, about 1,000 to about 75,000, about 1,000 to about 70,000, about 1,000 to about 65,000, about 1,000 to about 60,000, about 1,000 to about 55,000, about 1,000 to about 50,000, about 1,000 to about 45,000, about 1,000 to about 40,000, about 1,000 to about 35,000, about 1,000 to about 30,000, about 1,000 to about 25,000, about 1,000 to about 20,000, about 1,000 to about 15,000, about 1,000 to about 10,000, about 1,000 to about 7,500, about 1,000 to about 5,000, about 1,000 to about 4,000, about 1,000 to about 3,000, about 1,000 to about 2,000, about 2,000 to about 10,000,000, about 2,000 to about 9,000,000, about 2,000 to about 8,000,000, about 2,000 to about 7,000,000, about 2,000 to about 6,000,000, about 2,000 to about 5,000,000 , about 2,000 to about 4,000,000, about 2,000 to about 3,000,000, about 2,000 to about 2,000,000, about 2,000 to about 1,000,000, about 2,000 to about 800,000, about 2,000 to about 600,000, about 2,000 to about 400,000, about 2,000 to about 200,000, about 2,000 to about 100,000, about 2,000 to about 80,000, about 2,000 to about 75,000, about 2,000 to about 70,000, about 2,000 to about 65,000, about 2,000 to about 60,000, about 2,000 to about 55,000, about 2,000 to about 50,000, about 2,000 to about 45,000, about 2,000 to about 40,000, about 2,000 to about 35,000, about 2,000 to about 30,000, about 2,000 to about 25,000, about 2,000 to about 20,000, about 2,000 to about 15,000, about 2,000 to about 10,000, about 2,000 to about 7,500, about 2,000 to about 5,000, about 2,000 to about 4,000, about 2,000 to about 3,000, about 3,000 to about 10,000,000, about 3,000 to about 9,000,000, about 3,000 to about 8,000,000, about 3,000 to about 7,000 00,000, about 3,000 to about 6,000,000, about 3,000 to about 5,000,000, about 3,000 to about 4,000,000, about 3,000 to about 3,000,000, about 3,000 to about 2,000,000, about 3,000 to about 1,000,000, about 3,000 to about 800,000, about 3,000 to about 600,000, about 3,000 to about 400,000, about 3,000 to about 200,000, about 3,000 to about 100,000, about 3,000 to about 80,000, about 3,000 to about 75,000, about 3,000 to about 70,000, about 3,000 to about 65,000, about 3,000 to about 60,000, about 3,000 to about 55,000, about 3,000 to about 50,000, about 3,000 to about 45,000, about 3,000 to about 40,000, about 3,000 to about 35,000, about 3,000 to about 30,000, about 3,000 to about 25,000, about 3,000 to about 20,000, about 3,000 to about 15,000, about 3,000 to about 10,000, about 3,000 to about 7,500, about 3,000 to about 5,000, about 3,000 to about 4,000, about 4,000 to about 10,000,000, about 4,000 to about 9,000,000, about from about 4,000 to about 8,000,000, from about 4,000 to about 7,000,000, from about 4,000 to about 6,000,000, from about 4,000 to about 5,000,000, from about 4,000 to about 4,000,000, from about 4,000 to about 3,000,000, from about 4,000 to about 2,000,000, from about 4,000 to about 1,000,000, from about 4,000 to about 800,000, from about 4,000 to about 600,000, from about 4,000 to about 400,000, from about 4,000 to about 200,000, from about 4,000 to about 100,000, from about 4,000 to about 80,000, from about 4,000 to about 75, 000, about 4,000 to about 70,000, about 4,000 to about 65,000, about 4,000 to about 60,000, about 4,000 to about 55,000, about 4,000 to about 50,000, about 4,000 to about 45,000, about 4,000 to about 40,000, about 4,000 to about 35,000, about 4,000 to about 30,000, about 4,000 to about 25,000, about 4,000 to about 20,000, about 4,000 to about 15,000, about 4,000 to about 10,000, about 4,000 to about 7,500, about 4,000 to about 5,000, about 5,000 to about 10,000,000, about 5, from about 5,000 to about 9,000,000, from about 5,000 to about 8,000,000, from about 5,000 to about 7,000,000, from about 5,000 to about 6,000,000, from about 5,000 to about 5,000,000, from about 5,000 to about 4,000,000, from about 5,000 to about 3,000,000, from about 5,000 to about 2,000,000, from about 5,000 to about 1,000,000, from about 5,000 to about 800,000, from about 5,000 to about 600,000, from about 5,000 to about 400,000, from about 5,000 to about 200,000, from about 5,000 to about 100,000, from about 5,000 to about 80000, about 5,000 to about 75,000, about 5,000 to about 70,000, about 5,000 to about 65,000, about 5,000 to about 60,000, about 5,000 to about 55,000, about 5,000 to about 50,000, about 5,000 to about 45,000, about 5,000 to about 40,000, about 5,000 to about 35,000, about 5,000 to about 30,000, about 5,000 to about 25,000, about 5,000 to about 20,000, about 5,000 to about 15,000, about 5,000 to about 10,000, about 5,000 to about 7,500, about 7,500 to about 10,000,000, about 7,500 to about 9,000,000, about 7,500 to about 8,000,000, about 7,500 to about 7,000,000, about 7,500 to about 6,000,000, about 7,500 to about 5,000,000, about 7,500 to about 4,000,000, about 7,500 to about 3,000,000, about 7,500 to about 2,000,000, about 7,500 to about 1,000,000, about 7,500 to about 800,000, about 7,500 to about 600,000, about 7,500 to about 400,000, about 7,500 to about 200,000, about 7,500 to about 100,000, about 7,500 to about 80,000, about 7,500 to about 75,000, about 7,500 to about 70,000, about 7,500 to about 65,000, about 7,500 to about 60,000, about 7,500 to about 55,000, about 7,500 to about 50,000, about 7,500 to about 45,000, about 7,500 to about 40,000, about 7,500 to about 35,000, about 7,500 to about 30,000, about 7,500 to about 25,000, about 7,500 to about 20,000, about 7,500 to about 15,000, about 7,500 to about 10,000, about 10,000 to about 10,000,000, about 10,000 to about 9, 000,000, about 10,000 to about 8,000,000, about 10,000 to about 7,000,000, about 10,000 to about 6,000,000, about 10,000 to about 5,000,000, about 10,000 to about 4,000,000, about 10,000 to about 3,000,000, about 10,000 to about 2,000,000, about 10,000 to about 1,000,000, about 10,000 to about 800,000, about 10,000 to about 600,000, about 10,000 to about 400,000, about 10,000 to about 200,000, about 10,000 to about 100,000, about 10,000 to about 80,000, about 10,000 to about 75,000, about 10,000 to about 70,000, about 10,000 to about 65,000, about 10,000 to about 60,000, about 10,000 to about 55,000, about 10,000 to about 50,000, about 10,000 to about 45,000, about 10,000 to about 40,000, about 10,000 to about 35,000, about 10,000 to about 30,000, about 10,000 to about 25,000, about 10,000 to about 20,000, about 10,000 to about 15,000, about 15,000 to about 10,000,000, about 15,000 to about 9 ,000,000, about 15,000 to about 8,000,000, about 15,000 to about 7,000,000, about 15,000 to about 6,000,000, about 15,000 to about 5,000,000, about 15,000 to about 4,000,000, about 15,000 to about 3,000,000, about 15,000 to about 2,000,000, about 15,000 to about 1,000,000, about 15,000 to about 800,000, about 15,000 to about 600,000, about 15,000 to about 400,000, about 15,000 to about 200,000, about 15,000 to about 100,000, about 15, 000 to about 80,000, about 15,000 to about 75,000, about 15,000 to about 70,000, about 15,000 to about 65,000, about 15,000 to about 60,000, about 15,000 to about 55,000, about 15,000 to about 50,000, about 15,000 to about 45,000, about 15,000 to about 40,000, about 15,000 to about 35,000, about 15,000 to about 30,000, about 15,000 to about 25,000, about 15,000 to about 20,000, about 20,000 to about 10,000,000, about 20,000 to about 9,000,000, about 20,000 to about 8,000,000, about 20,000 to about 7,000,000, about 20,000 to about 6,000,000, about 20,000 to about 5,000,000, about 20,000 to about 4,000,000, about 20,000 to about 3,000,000, about 20,000 to about 2,000,000, about 20,000 to about 1,000,000, about 20,000 to about 800,000, about 20,000 to about 600,000, about 20,000 to about 400,000, about 20,000 to about 200,000, about 20,000 to about 100,000, about 20,000 to about 80,000, about 20,000 to about 75,000, about 20,000 to about 70,000, about 20,000 to about 65,000, about 210,000 to about 60,000, about 20,000 to about 55,000, about 20,000 to about 50,000, about 20,000 to about 45,000, about 20,000 to about 40,000, about 20,000 to about 35,000, about 20,000 to about 30,000, about 20,000 to about 25,000, about 25,000 to about 10,000,000, about 25,000 to about 9,000,000, about 25,000 to about 8,000,000, about 25,000 to about 7,000,000, about 25,000 to about 6,000,000, about 25,000 to about 5,000,000, about 25,000 to about 4,000,000, about 25,000 to about 3,000,000, about 25,000 to about 2,000,000, about 25,000 to about 1,000,000, about 25,000 to about 800,000, about 25,000 to about 600,000, about 25,000 to about 400,000, about 25,000 to about 200,000, about 25,000 to about 100,000, about 25,000 to about 80,000, about 25,000 to about 75,000, about 25,000 to about 70,000, about 25 ,000 to about 65,000, about 25,000 to about 60,000, about 25,000 to about 55,000, about 25,000 to about 50,000, about 25,000 to about 45,000, about 25,000 to about 40,000, about 25,000 to about 35,000, about 25,000 to about 30,000, about 30,000 to about 10,000,000, about 30,000 to about 9,000,000, about 30,000 to about 8,000,000, about 30,000 to about 7,000,000, about 30,000 to about 6,000,000, about 30,000 to about 5,000,000, about 30,000 to about 4 ,000,000, about 30,000 to about 3,000,000, about 30,000 to about 2,000,000, about 30,000 to about 1,000,000, about 30,000 to about 800,000, about 30,000 to about 600,000, about 30,000 to about 400,000, about 30,000 to about 200,000, about 30,000 to about 100,000, about 30,000 to about 80,000, about 30,000 to about 75,000, about 30,000 to about 70,000, about 30,000 to about 65,000, about 30,000 to about 60,000, about 30,000 to about 55,000, about 30,000 to about 50,000, about 30,000 to about 45,000, about 30,000 to about 40,000, about 30,000 to about 35,000, about 35,000 to about 10,000,000, about 35,000 to about 9,000,000, about 35,000 to about 8,000,000, about 35,000 to about 7,000,000, about 35,000 to about 6,000,000, about 35,000 to about 5,000,000, about 35,000 to about 4,000,000, about 35,000 to about 3,000,000, about 35,000 to about 2,000,000, about 35,000 to about 1,000,000 00, about 35,000 to about 800,000, about 35,000 to about 600,000, about 35,000 to about 400,000, about 35,000 to about 200,000, about 35,000 to about 100,000, about 35,000 to about 80,000, about 35,000 to about 75,000, about 35,000 to about 70,000, about 35,000 to about 65,000, about 35,000 to about 60,000, about 35,000 to about 55,000, about 35,000 to about 50,000, about 35,000 to about 45,000, about 35,000 to about 40,000, about 40,000 to about 10,000, 00, about 40,000 to about 9,000,000, about 40,000 to about 8,000,000, about 40,000 to about 7,000,000, about 40,000 to about 6,000,000, about 40,000 to about 5,000,000, about 40,000 to about 4,000,000, about 40,000 to about 3,000,000, about 40,000 to about 2,000,000, about 40,000 to about 1,000,000, about 40,000 to about 800,000, about 40,000 to about 600,000, about 40,000 to about 400,000, about 40,000 to about 200,000, about 40,000 to about 100,000, about 40,000 to about 80,000, about 40,000 to about 75,000, about 40,000 to about 70,000, about 40,000 to about 65,000, about 40,000 to about 60,000, about 40,000 to about 55,000, about 40,000 to about 50,000, about 40,000 to about 45,000, about 45,000 to about 10,000,000, about 45,000 to about 9,000,000, about 45,000 to about 8,000,000, about 45,000 to about 7,000,000, about 45,000 to about 6,000,000, about 45,000 to about 5,000,000, about 45,000 to about 4,000,000, about 45,000 to about 3,000,000, about 45,000 to about 2,000,000, about 45,000 to about 1,000,000, about 45,000 to about 800,000, about 45,000 to about 600,000, about 45,000 to about 400,000, about 45,000 to about 200,000, about 45,000 to about 100,000, about 45,000 to about 80,000, about 45,000 to about 75,000, about 45,000 to about 70,000, about 45,000 to about 65,000, about 45,000 to about 60,000. 00 to about 55,000, about 45,000 to about 50,000, about 50,000 to about 10,000,000, about 50,000 to about 9,000,000, about 50,000 to about 8,000,000, about 50,000 to about 7,000,000, about 50,000 to about 6,000,000, about 50,000 to about 5,000,000, about 50,000 to about 4,000,000, about 50,000 to about 3,000,000, about 50,000 to about 2,000,000, about 50,000 to about 1,000,000, about 50,000 to about 800,000, about 50,000 to about 600,000 0, about 50,000 to about 400,000, about 50,000 to about 200,000, about 50,000 to about 100,000, about 50,000 to about 80,000, about 50,000 to about 75,000, about 50,000 to about 70,000, about 50,000 to about 65,000, about 50,000 to about 60,000, about 50,000 to about 55,000, about 55,000 to about 10,000,000, about 55,000 to about 9,000,000, about 55,000 to about 8,000,000, about 55,000 to about 7,000,000, about 55,000 to about 6,000,000, 00 to about 5,000,000, about 55,000 to about 4,000,000, about 55,000 to about 3,000,000, about 55,000 to about 2,000,000, about 55,000 to about 1,000,000, about 55,000 to about 800,000, about 55,000 to about 600,000, about 55,000 to about 400,000, about 55,000 to about 200,000, about 55,000 to about 100,000, about 55,000 to about 80,000, about 55,000 to about 75,000, about 55,000 to about 70,000, about 55,000 to about 65,000, about 55,000 to about 60,000, about 60,000 to about 10,000,000, about 60,000 to about 9,000,000, about 60,000 to about 8,000,000, about 60,000 to about 7,000,000, about 60,000 to about 6,000,000, about 60,000 to about 5,000,000, about 60,000 to about 4,000,000, about 60,000 to about 3,000,000, about 60,000 to about 2,000,000, about 60,000 to about 1,000,000, about 60,000 to about 800,000, about 60,000 to about 600,000, about 60,000 to about 400,000, about 60, 000 to about 200,000, about 60,000 to about 100,000, about 60,000 to about 80,000, about 60,000 to about 75,000, about 60,000 to about 70,000, about 60,000 to about 65,000, about 65,000 to about 10,000,000, about 65,000 to about 9,000,000, about 65,000 to about 8,000,000, about 65,000 to about 7,000,000, about 65,000 to about 6,000,000, about 65,000 to about 5,000,000, about 65,000 to about 4,000,000, about 65,000 to about 3,000,000, about 65 ,000 to about 2,000,000, about 65,000 to about 1,000,000, about 65,000 to about 800,000, about 65,000 to about 600,000, about 65,000 to about 400,000, about 65,000 to about 200,000, about 65,000 to about 100,000, about 65,000 to about 80,000, about 65,000 to about 75,000, about 65,000 to about 70,000, about 70,000 to about 10,000,000, about 70,000 to about 9,000,000, about 70,000 to about 8,000,000, about 70,000 to about 7,000,000 00 to about 6,000,000, about 70,000 to about 5,000,000, about 70,000 to about 4,000,000, about 70,000 to about 3,000,000, about 70,000 to about 2,000,000, about 70,000 to about 1,000,000, about 70,000 to about 800,000, about 70,000 to about 600,000, about 70,000 to about 400,000, about 70,000 to about 200,000, about 70,000 to about 100,000, about 70,000 to about 90,000, about 70,000 to about 80,000, about 80,000 to about 10,000,000, about 80,000000 to about 9,000,000, about 80,000 to about 8,000,000, about 80,000 to about 7,000,000, about 80,000 to about 6,000,000, about 80,000 to about 5,000,000, about 80,000 to about 4,000,000, about 80,000 to about 3,000,000, about 80,000 to about 2,000,000, about 80,000 to about 1,000,000, about 80,000 to about 800,000, about 80,000 to about 600,000, about 80,000 to about 400,000, about 80,000 to about 200,000, about 80,000 to about 100, 000, about 80,000 to about 90,000, about 90,000 to about 10,000,000, about 90,000 to about 9,000,000, about 90,000 to about 8,000,000, about 90,000 to about 7,000,000, about 90,000 to about 6,000,000, about 90,000 to about 5,000,000, about 90,000 to about 4,000,000, about 90,000 to about 3,000,000, about 90,000 to about 2,000,000, about 90,000 to about 1,000,000, about 90,000 to about 800,000, about 90,000 to about 600,000, about 90, 000 to about 400,000, about 90,000 to about 200,000, about 90,000 to about 100,000, about 100,000 to about 10,000,000, about 100,000 to about 9,000,000, about 100,000 to about 8,000,000, about 100,000 to about 7,000,000, about 100,000 to about 6,000,000, about 100,000 to about 5,000,000, about 100,000 to about 4,000,000, about 100,000 to about 3,000,000, about 100,000 to about 2,000,000, about 100,000 to about 1,000,000, from about 100,000 to about 800,000, from about 100,000 to about 600,000, from about 100,000 to about 400,000, from about 100,000 to about 200,000, from about 200,000 to about 10,000,000, from about 200,000 to about 9,000,000, from about 200,000 to about 8,000,000, from about 200,000 to about 7,000,000, from about 200,000 to about 6,000,000, from about 200,000 to about 5,000,000, from about 200,000 to about 4,000,000, from about 200,000 to about 3,000,000, from about 200,000 to about 2,000,000, about 200,000 to about 1,000,000, about 200,000 to about 800,000, about 200,000 to about 600,000, about 200,000 to about 400,000, about 400,000 to about 10,000,000, about 400,000 to about 9,000,000, about 400,000 to about 8,000,000, about 400,000 to about 7,000,000, about 400,000 to about 6,000,000, about 400,000 to about 5,000,000, about 400,000 to about 4,000,000, about 400,000 to about 3,000,000, about 400,000 to about 2,000,000, about 400,000 to about 1,000,000, about 400,000 to about 800,000, about 400,000 to about 600,000, about 600,000 to about 10,000,000, about 600,000 to about 9,000,000, about 600,000 to about 8,000,000, about 600,000 to about 7,000,000, about 600,000 to about 6,000,000, about 600,000 to about 5,000,000, about 600,000 to about 4,000,000, about 600,000 to about 3,000,000, about 600,000 to about 2,000,000, about 6 00,000 to about 1,000,000, about 600,000 to about 800,000, about 800,000 to about 10,000,000, about 800,000 to about 9,000,000, about 800,000 to about 8,000,000, about 800,000 to about 7,000,000, about 800,000 to about 6,000,000, about 800,000 to about 5,000,000, about 800,000 to about 4,000,000, about 800,000 to about 3,000,000, about 800,000 to about 2,000,000, about 800,000 to about 1,000,000, about 1,000,000 to about 10,000,000, about 1,000,000 to about 9,000,000, about 1,000,000 to about 8,000,000, about 1,000,000 to about 7,000,000, about 1,000,000 to about 6,000,000, about 1,000,000 to about 5,000,000, about 1,000,000 to about 4,000,000, about 1,000,000 to about 3,000,000, about 1,000,000 to about 2,000,000, about 2,000,000 to about 10,000,000, about 2,000,000 to about 9,000,000, about 2,000,000 to about 8,000,000, about 2,000,000 to about 7,000,000, about 2,000,000 to about 6,000,000, about 2,000,000 to about 5,000,000, about 2,000,000 to about 4,000,000, about 2,000,000 to about 3,000,000, about 3,000,000 to about 10,000,000, about 3,000,000 to about 9,000,000, about 3,000,000 to about 8,000,000, about 3,000,000 to about 10,000,000. 00,000 to about 7,000,000, about 3,000,000 to about 6,000,000, about 3,000,000 to about 5,000,000, about 3,000,000 to about 4,000,000, about 4,000,000 to about 10,000,000, about 4,000,000 to about 9,000,000, about 4,000,000 to about 8,000,000, about 4,000,000 to about 7,000,000, about 4,000,000 to about 6,000,000, about 4,000,000 to about 5,000,000, about 5,000,000 to about 10,000,000, about 5,000,000 to about 9,000,000, about 5,000,000 to about 8,000,000, about 5,000,000 to about 7,000,000, about 5,000,000 to about 6,000,000, about 6,000,000 to about 10,000,000, about 6,000,000 to about 9,000,000. 00, about 6,000,000 to about 8,000,000, about 6,000,000 to about 7,000,000, about 7,000,000 to about 10,000,000, about 7,000,000 to about 9,000,000, about 7,000,000 to about 8,000,000, about 8,000,000 to about 10,000,000, about 8,000,000 to about 9,000,000, or about 9,000,000 to about 10,000,000.

[0068] The phrase "antigen density" means the number of METs present on the surface of a target mammalian cell or the average number of METs present on the surface of a population of target mammalian cells of a particular type. "Antigen density" can be measured using, for example, a Quantibright bead kit or a radiolabel (e.g., BD Biosciences PE Phycoerythrin Fluorescence Quantitation Kit, catalog number 340495).

[0069] The phrase "amino acid is substituted with histidine" means that an amino acid residue in a reference polypeptide sequence that is not histidine is substituted with histidine. Non-limiting methods for substituting amino acid residues in a reference polypeptide with histidine are described herein. Additional methods for substituting amino acid residues in a reference polypeptide with histidine are known in the art.

[0070] The phrase "amino acid is substituted with alanine" means that an amino acid residue in a reference polypeptide sequence that is histidine is replaced with alanine. Non-limiting methods for substituting alanine for histidine in a reference polypeptide are described herein. Additional methods for substituting alanine for histidine in a reference polypeptide are known in the art.

[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Methods and materials for use in the present invention are described herein, and other suitable methods and materials known in the art may also be used. The materials, methods, and examples are merely illustrative and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, this specification (including definitions) shall prevail.

[0072] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 : SDS PAGE of histidine scan and alanine scan of terituzumab. Harvested Expi293 cell culture supernatant was loaded onto a non-reducing SDS PAGE gel to confirm the expression of terituzumab and histidine scan and alanine scan variants. Arrows show the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT0886 is terituzumab, and the remaining lanes (MYT0887-MYT0924) are terituzumab heavy chain histidine scan and alanine scan variants.

[0074] Figures 2a to 2am Figure 2: Binding of terituzumab starting ABPC and histidine- and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT0886 (terituzumab) and MYT0887-MYT0924 (heavy chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0075] Figure 3: SDS PAGE of histidine scan and alanine scan of terituzumab. Harvested Expi293 cell culture supernatant was loaded onto a non-reducing SDS PAGE gel to confirm the expression of terituzumab and histidine scan and alanine scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT0886 is terituzumab, and the remaining lanes (MYT2028-MYT2058) are terituzumab heavy chain histidine scan and alanine scan variants.

[0076] Figures 4a to 4af : Binding of terituzumab starting ABPC and histidine-scan and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT0886 (terituzumab) and MYT2028-MYT2058 (light chain histidine-scan and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0077] Figure 5 Figure 3: SDS PAGE of histidine- and alanine-scanned terituzumab. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of histidine- and alanine-scanned terituzumab variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT2018-MYT2027 are combined histidine- and alanine-scanned variants of the terituzumab heavy chain.

[0078] Figures 6a to 6j : Binding of histidine-scanning and alanine-scanning variants of terituzumab to MET as determined by biofilm interferometry. As illustrated in the figure, MYT2018-MYT2027 (heavy chain combination histidine-scanning and alanine-scanning variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0079] Figure 7 Figure 2: SDS PAGE of histidine- and alanine-scanned terituzumab. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of histidine- and alanine-scanned terituzumab variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4201-MYT4210 are combined histidine- and alanine-scanned terituzumab light chain variants.

[0080] Figures 8a to 8jFigure 2: Binding of histidine- and alanine-scan variants of terituzumab to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4201-MYT4210 (light chain combination histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0081] Figure 9 Figure 2: SDS PAGE of histidine- and alanine-scanned Terituzumab. Harvested Expi293 cell culture supernatant was loaded onto a non-reducing SDS PAGE gel to confirm expression of the histidine- and alanine-scanned Terituzumab variants. Arrows indicate the corresponding sizes of the IgG on the non-reducing SDS PAGE gel. MYT3451-MYT3492, MYT3603-MYT3616, and MYT4211-MYT4220 are paired heavy and light chain histidine- and alanine-scanned variants of Terituzumab, combined light chain histidine- and alanine-scanned variants, or light chain combined histidine- and alanine-scanned variants with heavy chain histidine- and alanine-scanned variants, or heavy chain combined histidine- and alanine-scanned variants.

[0082] Figures 10a to 10bn Binding of histidine-scan and alanine-scan variants of terituzumab to MET as determined by biofilm interferometry. MYT3451-MYT3492, MYT3603-MYT3616, and MYT4211-MYT4220, paired heavy and light chain histidine-scan and alanine-scan variants, combined light chain histidine-scan and alanine-scan variants, or light chain combined histidine-scan variants with heavy chain histidine-scan and alanine-scan variants, or heavy chain combined histidine-scan and alanine-scan variants, were captured on an anti-human Fc biosensor and bound to MET at low or high pH, as indicated.

[0083] Figure 11 Figure 2: SDS PAGE of histidine- and alanine-scanned terituzumab. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of histidine- and alanine-scanned terituzumab variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT4951-MYT4989 are combined histidine- and alanine-scanned terituzumab heavy chain variants.

[0084] Figure 12: Internalization and endolysosomal delivery of histidine-scanning and alanine-scanning variants of terituzumab in Detroit 562 cells. Using Incucyte Human FabFluor-pH Red Antibody Labeling Reagent, MYT4894 (terituzumab) and MYT4953 and MYT4970, heavy chain combination histidine-scanning and alanine-scanning variants were measured on Detroit 562 cells at the indicated time points and final concentrations of ABPC. The fold increase in internalization and endolysosomal delivery is indicated by the numbers for each variant above.

[0085] Figures 13a to 13b Binding of histidine- and alanine-scan variants of terituzumab to MET as determined by biofilm interferometry. As illustrated, MYT4953-MYT4970 (combined histidine- and alanine-scan heavy chain variants) were captured on an anti-human Fc biosensor and associated with MET at pH 7.4. Dissociation occurred at either pH 7.4 (black trace) or pH 5.4 (grey trace).

[0086] Figure 14 Figure 2: SDS PAGE of histidine- and alanine-scanned Terituzumab. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of histidine- and alanine-scanned Terituzumab variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4990-MYT4994 are combined histidine- and alanine-scanned Terituzumab light chain variants.

[0087] Figure 15 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, heavy chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0088] Figure 16 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, light chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0089] Figure 17 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0090] Figure 18 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0091] Figure 19 : Construct identifiers of the corresponding table of SEQ ID NOs. Constructs, paired heavy and light chain variants (combined light chain histidine and alanine scan variants or light chain combined histidine and alanine scan variants with heavy chain histidine and alanine scan variants or heavy chain combined histidine and alanine scan variants) are listed in the first column of the table, listing SEQ ID NOs and corresponding to the construct on the left and the appropriate heavy and / or light chain classification along the top.

[0092] Figure 20 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0093] Figure 21 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0094] Figure 22 Figure 2: SDS PAGE of imatinib histidine scan and alanine scan. The Expi293 cell culture supernatant after harvest is loaded on a non-reducing SDS PAGE gel to confirm the expression of imatinib and histidine scan and alanine scan variants. The arrows show the corresponding sizes of IgG on a non-reducing SDS PAGE gel. MYT2313 is imatinib, and the remaining lanes (MYT2314-MYT2348) are imatinib heavy chain histidine scan and alanine scan variants.

[0095] Figures 23a to 23aj Figure 2: Binding of imatinib starting ABPC and histidine- and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT2313 (imatinib) and MYT2314-MYT2348 (heavy chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0096] Figure 24: SDS PAGE of histidine scan and alanine scan of imatinib. The Expi293 cell culture supernatant after harvest was loaded on a non-reducing SDS PAGE gel to confirm the expression of imatinib and histidine scan and alanine scan variants. The arrows show the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT3958-MYT3985 are histidine scan and alanine scan variants of the light chain of imatinib.

[0097] Figures 25a to 25ab : The binding of histidine-scanning and alanine-scanning variants of imatinib to MET determined by biofilm interferometry. As illustrated in the figure, MYT3958-MYT3985 (light chain histidine-scanning and alanine-scanning variants) were captured on anti-human Fc biosensors and associated with MET at low or high pH.

[0098] Figure 26 Figure 2: SDS PAGE of histidine scan and alanine scan of imatinib. The culture supernatant of Expi293 cells after harvest was loaded onto a non-reducing SDS PAGE gel to confirm the expression of histidine scan and alanine scan variants of imatinib. The arrows show the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT2848-MYT2867 are histidine scan and alanine scan variants of the imatinib heavy chain combination.

[0099] Figures 27a to 27t Figure 2: Binding of histidine- and alanine-scan variants of imatinib to MET as determined by biofilm interferometry. As illustrated in the figure, MYT2848-MYT2867 (heavy chain combined histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0100] Figure 28 Figure 2: SDS PAGE of histidine scan and alanine scan of imatinib. The culture supernatant of Expi293 cells after harvest was loaded onto a non-reducing SDS PAGE gel to confirm the expression of histidine scan and alanine scan variants of imatinib. The arrows show the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT4326-MYT4345 are histidine scan and alanine scan variants of the imatinib light chain combination.

[0101] Figures 29a to 29t: Binding of histidine-scan and alanine-scan variants of imatinib to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4326-MYT4345 (light chain combination histidine-scan and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0102] Figure 30 Figure 2: SDS PAGE of imatuzumab histidine scan and alanine scan. The Expi293 cell culture supernatant after harvest was loaded on a non-reducing SDS PAGE gel to confirm the expression of imatuzumab histidine scan and alanine scan variants. Arrows show the corresponding sizes of IgG on a non-reducing SDS PAGE gel. MYT3999-MYT4042 are heavy chain and light chain histidine scan variants and light chain alanine scan variants, combination light chain histidine and alanine scan variants or light chain combination histidine scan variants and alanine scan variants and heavy chain histidine and alanine scan variants or heavy chain combination histidine scan variants and alanine scan variants of imatuzumab pairing.

[0103] Figures 31a to 31ar : Binding of histidine- and alanine-scan variants of imatinib to MET as determined by biofilm interferometry. As illustrated in the figure, MYT3999-MYT4042 paired heavy and light chain histidine- and alanine-scan variants (combined light chain histidine- and alanine-scan variants or light chain combined histidine- and alanine-scan variants with heavy chain histidine- and alanine-scan variants or heavy chain combined histidine- and alanine-scan variants) were captured on an anti-human Fc sensor and associated with MET at low or high pH.

[0104] Figure 32 Figure 2: SDS PAGE of histidine scan and alanine scan of imatinib. The culture supernatant of Expi293 cells after harvest was loaded onto a non-reducing SDS PAGE gel to confirm the expression of histidine scan and alanine scan variants of imatinib. The arrows show the corresponding sizes of IgG on the non-reducing SDS PAGE gel. MYT4995-MYT5041 are histidine scan and alanine scan variants of the imatinib heavy chain combination.

[0105] Figure 33 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, heavy chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0106] Figure 34: Construct identifiers for the SEQ ID NO correspondence table. The constructs, light chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0107] Figure 35 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0108] Figure 36 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0109] Figure 37 : Construct identifiers of the corresponding table of SEQ ID NOs. Constructs, paired heavy and light chain variants (combined light chain histidine and alanine scan variants or light chain combined histidine and alanine scan variants with heavy chain histidine and alanine scan variants or heavy chain combined histidine and alanine scan variants) are listed in the first column of the table, listing SEQ ID NOs and corresponding to the construct on the left and the appropriate heavy and / or light chain classification along the top.

[0110] Figure 38 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0111] Figure 39 : SDS PAGE of hucMET27Gv1.3 Histidine and Alanine Scans. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 and the Histidine and Alanine Scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT3617 is hucMET27Gv1.3, and the remaining lanes (MYT3618-MYT3655) are hucMET27Gv1.3 heavy chain Histidine and Alanine Scan variants.

[0112] Figures 40a to 40amFigure 2: Binding of hucMET27Gv1.3 starting ABPC and histidine- and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT3617 (hucMET27Gv1.3) and MYT3618-MYT3655 (heavy chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0113] Figure 41 Figure 3: SDS PAGE of hucMET27Gv1.3 Histidine- and Alanine-scanned variants. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 and the Histidine- and Alanine-scanned variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT3656-MYT3686 are hucMET27Gv1.3 light chain Histidine- and Alanine-scanned variants.

[0114] Figures 42a to 42ae Figure 2: Binding of hucMET27Gv1.3 histidine scan and alanine scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT3656-MYT3686 (light chain histidine scan and alanine scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0115] Figure 43 Figure 3: SDS PAGE of hucMET27Gv1.3 Histidine and Alanine Scans. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 Histidine and Alanine Scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4285-MYT4304 are hucMET27Gv1.3 heavy chain variants with combined Histidine and Alanine Scans.

[0116] Figures 44a to 44t Figure 3: Binding of histidine- and alanine-scan variants of hucMET27Gv1.3 to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4285-MYT4304 (combination histidine- and alanine-scan variants of the heavy chain) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0117] Figure 45Figure 3: SDS PAGE of hucMET27Gv1.3 Histidine- and Alanine-scanned variants. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 Histidine- and Alanine-scanned variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4222-MYT4241 are hucMET27Gv1.3 light chain variants with combined Histidine- and Alanine-scanning.

[0118] Figures 46a to 46t : Binding of histidine- and alanine-scan variants of hucMET27Gv1.3 to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4222-MYT4241 (light chain combined histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0119] Figure 47 Figure 3: SDS PAGE of hucMET27Gv1.3 Histidine and Alanine Scans. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 Histidine and Alanine Scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT5296 and MYT5042-MYT5065 are combined Histidine and Alanine Scan variants of the hucMET27Gv1.3 heavy chain.

[0120] Figure 48 Figure 3: SDS PAGE of hucMET27Gv1.3 Histidine and Alanine Scans. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of hucMET27Gv1.3 Histidine and Alanine Scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT5066-MYT5121 are hucMET27Gv1.3 light chain variants with combined Histidine and Alanine Scans.

[0121] Figures 49a-49f: Internalization and endolysosomal delivery of histidine-scanning variants and alanine-scanning variants of HucMET27Gv1.3 in Detroit 562 cells. Using Incucyte Human FabFluor-pH red antibody labeling reagent, at the specified time points and final concentrations of ABPC, the internalization of histidine-scanning and alanine-scanning variants (as shown in the figure) of MYT4284 (hucMett27Gv1.3) and light chain combinations on Detroit 562 cells was determined. The fold increase in internalization and endolysosomal delivery is indicated by the numbers of the above-mentioned variants.

[0122] Figures 50a to 50v : Binding of histidine-scan and alanine-scan variants of hucMET27Gv1.3 to MET as measured by biofilm interferometry. As shown in the figure, histidine-scan and alanine-scan light chain variants of hucMET27Gv1.3 were captured on an anti-human Fc biosensor and bound to MET at pH 7.4. Dissociation was performed at pH 7.4 (black trace) or pH 5.4 (grey trace).

[0123] Figure 51 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, heavy chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0124] Figure 52 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, light chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0125] Figure 53 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0126] Figure 54 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0127] Figure 55: Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0128] Figure 56 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0129] Figure 57 : P3D12 histidine scan and alanine scan SDS PAGE. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 and histidine scan and alanine scan variants. Arrows indicate the corresponding sizes of IgG on non-reducing SDS PAGE gels. MYT3687 is P3D12, and the remaining lanes (MYT3688-MYT3726) are P3D12 heavy chain histidine scan and alanine scan variants.

[0130] Figures 58a to 58an Figure 2: Binding of P3D12 starting ABPC and histidine- and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT3687 (P3D12) and MYT3688-MYT3726 (heavy chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0131] Figure 59 Figure 2: SDS PAGE of P3D12 histidine scan and alanine scan. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 and histidine scan and alanine scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT3727-MYT3754 are P3D12 light chain histidine scan and alanine scan variants.

[0132] Figures 60a to 60ab Figure 2: Binding of P3D 12 histidine- and alanine-scan variants to MET as determined by biofilm interferometry. As illustrated in the figure, MYT3727-MYT3754 (light chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0133] Figure 61Figure 2: SDS PAGE of P3D12 histidine- and alanine-scanned variants. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 histidine- and alanine-scanned variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4306-MYT4325 are combined histidine- and alanine-scanned variants of the P3D12 heavy chain.

[0134] Figures 62a to 62t : Binding of histidine- and alanine-scan variants of P3D12 to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4306-MYT4325 (combination heavy chain histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0135] Figure 63 Figure 2: SDS PAGE of P3D12 histidine- and alanine-scanned variants. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 histidine- and alanine-scanned variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT4242-MYT4261 are combined histidine- and alanine-scanned variants of the P3D12 light chain.

[0136] Figures 64a to 64t : Binding of histidine- and alanine-scan variants of P3D12 to MET as determined by biofilm interferometry. As illustrated in the figure, MYT4242-MYT4261 (light chain combination histidine- and alanine-scan variants) were captured on an anti-human Fc biosensor and associated with MET at low or high pH.

[0137] Figure 65 Figure 2: SDS PAGE of P3D12 histidine- and alanine-scanned variants. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 histidine- and alanine-scanned variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT5122-MYT5221 are combined histidine- and alanine-scanned variants of the P3D12 heavy chain.

[0138] Figures 66a-66e: Internalization and endolysosomal delivery of histidine-scanning and alanine-scanning variants of P3D12 in Detroit 562 cells. Using Incucyte Human FabFluor-pH Red Antibody Labeling Reagent, histidine-scanning and alanine-scanning variants of MYT4305 (P3D 12) and heavy chain combinations (as shown in the figure) were determined for internalization on Detroit 562 cells at the indicated time points and final concentrations of ABPC. The fold increase in internalization and endolysosomal delivery is indicated by the numbers for each variant above.

[0139] Figures 67a-67e : Binding of histidine-scan and alanine-scan variants of P3D12 to MET as determined by biofilm interferometry. As shown in the figure, the heavy chain combination histidine-scan and alanine-scan variants of P3D12 were captured on an anti-human Fc biosensor and bound to MET at pH 7.4. Dissociation was performed at pH 7.4 (black trace) or pH 5.4 (grey trace).

[0140] Figure 68 Figure 2: SDS PAGE of P3D12 histidine and alanine scans. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 histidine and alanine scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gels. MYT5222-MYT5295 are combined histidine and alanine scan variants of the P3D12 light chain.

[0141] Figure 69 : Internalization and endolysosomal delivery of histidine-scanning and alanine-scanning variants of P3D12 in Detroit 562 cells. Using Incucyte Human FabFluor-pH Red antibody labeling reagent, the internalization of MYT4305 (P3D12) and the light chain combined histidine-scanning and alanine-scanning P3D12 variants MYT5237 on Detroit 562 cells was determined at the indicated time points and final concentrations of ABPC. The fold increase in internalization and endolysosomal delivery is indicated by the numbers for each variant above.

[0142] Figure 70 : Binding of histidine- and alanine-scan variants of P3D12 to MET as determined by biofilm interferometry. The light chain combination of histidine- and alanine-scan variants of P3D12, MYT5237, was captured on an anti-human Fc biosensor and associated with MET at pH 7.4. Dissociation was performed at pH 7.4 (black trace) or pH 5.4 (grey trace).

[0143] Figure 71 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, heavy chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0144] Figure 72 : Construct identifiers for the SEQ ID NO correspondence table. The constructs, light chain histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0145] Figure 73 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0146] Figure 74 : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0147] Figures 75a to 75b : Construct identifiers for the SEQ ID NO correspondence table. Constructs, heavy chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed and corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0148] Figures 76a to 76b : Construct identifiers for the SEQ ID NO correspondence table. Constructs, light chain combination histidine scan and alanine scan variants are listed in the first column of the table, with the SEQ ID NO listed corresponding to the construct on the left and the appropriate heavy and / or light chain class along the top.

[0149] Figure 77 : SDS PAGE for rearranged anti-MET aBPC. Harvested Expi293 cell culture supernatant was loaded onto a non-reducing SDS PAGE gel to confirm expression of the starting aBPC as well as histidine-scan and alanine-scan variants. Arrows indicate the corresponding sizes of IgG on the non-reducing SDS PAGE gel.

[0150] Figures 78a-78l: Binding of the starting ABPC and histidine- and alanine-scan variants to MET as determined by biofilm interferometry. The starting ABPC and histidine- and alanine-scan variants were captured on an anti-human Fc biosensor as illustrated and associated with MET at pH 7.4. Dissociation was performed at pH 7.4 (black trace) or pH 5.4 (grey trace).

[0151] Figures 79a-79f : Internalization and endolysosomal delivery of the starting anti-MET ABPC and histidine-scanning and alanine-scanning variants in Detroit 562 cells. Internalization of the starting ABPC and histidine-scanning and alanine-scanning variants as shown in the figure on Detroit 562 cells was determined using Incucyte Human FabFluor-pH Red Antibody Labeling Reagent at the indicated time points and final concentrations of ABPC. The fold increase in internalization and endolysosomal delivery is indicated by the number above for each variant.

[0152] Figures 80a-80d Table of rearranged ABPC construct identifiers. The IgG1 starting ABPC and histidine-scan and alanine-scan variants are listed in the first column. IgG1 with TH and YTE mutations. Constructs with the same heavy and light variable regions as the IgG1 construct in the same row are listed in the second column.

[0153] Figures 81a to 81aj : Internalization of anti-MET mAb in cells. As measured by the mean fluorescence intensity (as specified in the figure) on cells over 24 hours, the assay was performed as follows: Figures 81a-81aj Internalization and endolysosomal delivery of the anti-MET pH engineered antibody variants described in , the corresponding starting ABPC antibodies, a control IgG1 isotype control (BP0297, Bioxcell), and a vehicle control. Error bars represent standard deviations. Numbers above the bars represent fold changes relative to the corresponding starting ABPCs.

[0154] Figure 82 Figure 2: SDS PAGE of P3D12 His- and Alanine-scanned IgGs. Harvested Expi293 cell culture supernatants were loaded onto non-reducing SDS PAGE gels to confirm expression of P3D12 His- and Alanine-scanned IgGs. Arrows indicate the corresponding sizes of IgGs on the non-reducing SDS PAGE gels. MYT5342-MYT5381 are paired P3D12 heavy and light chain His- and Alanine-scanned IgGs, combined with either a light chain His- and Alanine-scanned IgG or a light chain His- and Alanine-scanned IgG with either a heavy chain His- and Alanine-scanned IgG or a heavy chain His- and Alanine-scanned IgG.

[0155] Figures 83a to 83an : Binding of histidine- and alanine-scan variants of P3D12 to MET as determined by biofilm interferometry. MYT5342-MYT5381, paired heavy and light chain histidine- and alanine-scan variants, combined light chain histidine- and alanine-scan variants, or light chain combined histidine- and alanine-scan variants, and heavy chain histidine- and alanine-scan variants or heavy chain combined histidine- and alanine-scan variants were captured on an anti-human Fc sensor and associated with MET at pH 7.4. Dissociation was performed at pH 7.4 (black trace) or pH 5.4 (grey trace).

[0156] Figure 84 : Construct identifiers of the corresponding table of SEQ ID NOs. Constructs, paired heavy and light chain variants (combined light chain histidine and alanine scan variants or light chain combined histidine and alanine scan variants with heavy chain histidine and alanine scan variants or heavy chain combined histidine and alanine scan variants) are listed in the first column of the table, listing SEQ ID NOs and corresponding to the construct on the left and the appropriate heavy and / or light chain classification along the top.

[0157] Figure 85 : Melting temperatures of selected anti-MET mAbs. The melting temperatures of the selected anti-MET mAbs listed in the table were determined by differential scanning calorimetry (DSF), and the resulting Sypro Orange signal was plotted as its first derivative. The melting temperature (Tm) was calculated as the local maximum of the plot and is shown in the table. DETAILED DESCRIPTION

[0158] Provided herein are antigen binding protein constructs (ABPCs) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell, wherein: (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0; and / or (b) the first antigen binding domain has a dissociation constant (K) at a pH of about 4.0 to about 6.5. D ) than K at a pH of about 7.0 to about 8.0 D In some examples of these ABPCs, the ABPC is degraded in the target mammalian cell after the ABPC is internalized by the target mammalian cell. Some examples of any ABPC described herein may also include a conjugated toxin, radioisotope, drug, or small molecule (e.g., fluorophore or dye).

[0159] Also provided are antigen binding protein constructs (ABPCs) comprising: a first antigen binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell; and a conjugated toxin, radioisotope, drug, or small molecule, wherein: (a) the first antigen binding domain has a faster off-rate at a pH of about 4.0 to about 6.5 than at a pH of about 7.0 to about 8.0; and / or the dissociation constant (K) of the first antigen binding domain at a pH of about 4.0 to about 6.5 is greater than that of the first antigen binding domain. D ) than K at a pH of about 7.0 to about 8.0 D and (b) the composition comprising the ABPCs provides one or more (e.g., two or three) of the following: an increase (e.g., a detectable increase) in toxin release in target mammalian cells compared to a composition comprising the same amount of a control ABPC; an increase (e.g., a detectable increase) in killing of target mammalian cells compared to a composition comprising the same amount of a control ABPC; and an increase (e.g., a detectable increase) in endolysosomal delivery in target mammalian cells compared to a composition comprising the same amount of a control ABPC.

[0160] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of terituzumab having one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids substituted with histidine; and a light chain variable domain of terituzumab having one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids substituted with histidine. In some examples of any ABPCs described herein, the heavy chain variable domain of terituzumab comprises SEQ ID NO: 1. In some examples of any ABPCs described herein, the light chain variable domain of terituzumab comprises SEQ ID NO: 2.

[0161] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 3-5 are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 6-8 are substituted with histidine. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 3-5 are substituted with histidine; and a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 6-8 are substituted with histidine.

[0162] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain comprises histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 1 selected from the group consisting of 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 2 selected from the group consisting of 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101.In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain comprises histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107; and NO:2, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO:2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101.

[0163] In some examples of any of the ABPCs described herein, the heavy chain variable domain includes a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0164] Table 1. Exemplary combinations of amino acid positions in SEQ ID NO: 1 that can be substituted with histidine

[0165]

[0166]

[0167] In some examples of any of the ABPCs described herein, the light chain variable domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain includes histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 2 listed in Table 2.

[0168] In some examples of any of the ABPCs described herein, the first antigen binding domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:2, wherein the light chain variable domain includes an alanine at position 38 in SEQ ID NO:2.

[0169] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain comprises an alanine at position 38 of SEQ ID NO: 2; and a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain comprises an alanine at position 38 of SEQ ID NO: 2. a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in NO: 1 selected from the group consisting of 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107.

[0170] In some examples of any of the ABPCs described herein, the first antigen binding domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 2 selected from the group consisting of 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101, and wherein the light chain variable domain includes an alanine at position 38 in SEQ ID NO: 2. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 2 selected from the group consisting of 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101, and wherein the light chain variable domain comprises an alanine at position 38 in SEQ ID NO: 2; and NO: 1 with at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identity, wherein the heavy chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 1 selected from the group consisting of 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107.

[0171] In some examples of any of the ABPCs described herein, the light chain variable domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:2, wherein the light chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO:2 listed in Table 2 and wherein the light chain variable domain includes an alanine at position 38 in SEQ ID NO:2.

[0172] Table 2. Exemplary combinations of amino acid positions in SEQ ID NO: 2 that can be substituted with histidine

[0173]

[0174]

[0175]

[0176]

[0177] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain comprises histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1; and a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 2, wherein the light chain variable domain comprises histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 2 listed in Table 2.

[0178] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a light chain variable domain comprising SEQ ID NO: 2, and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes histidine at any specific combination of one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0179] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 25 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0180] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 28 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0181] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 29 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0182] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 30 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0183] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 31 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0184] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 32 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0185] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 34 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0186] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 35 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0187] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 36 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0188] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 37 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0189] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 54 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0190] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 55 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0191] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 59 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0192] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 60 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0193] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 95 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0194] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 99 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0195] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at position 101 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0196] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes an alanine at position 38 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 1 listed in Table 1.

[0197] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine; and a light chain variable domain of terituzumab in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the heavy chain variable domain of terituzumab comprises SEQ ID NO: 1. In some examples of any ABPCs described herein, the light chain variable domain of terituzumab comprises SEQ ID NO: 2.

[0198] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NO: 3-5 are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NO: 6-8 are substituted with alanine. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NO: 3-5 are substituted with alanine; and a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NO: 6-8 are substituted with alanine.

[0199] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises the heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44 NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0200] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain of SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or SEQ ID NO: 81. NO:81.

[0201] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 2 and a heavy chain variable domain comprising SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44 NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50.

[0202] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 51 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0203] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 52 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0204] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 53 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0205] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 54 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0206] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 55 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0207] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 56 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0208] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 57 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0209] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 58 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0210] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 59 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0211] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 60 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0212] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 61 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0213] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 62 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0214] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 63 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0215] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 64 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0216] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 65 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0217] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 66 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0218] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 67 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0219] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 68 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0220] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 69 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0221] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 70 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0222] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 71 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0223] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 72 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0224] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 73 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0225] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 74 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0226] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 75 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0227] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 76 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0228] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 77 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0229] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 78 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0230] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 79 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0231] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 80 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0232] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 81 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50.

[0233] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111 NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.

[0234] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 82 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO: 79, SEQ ID NO: 80 or SEQ ID NO: 81.

[0235] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 83 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0236] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 84 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0237] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 85 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO: 79, SEQ ID NO: 80 or SEQ ID NO: 81.

[0238] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 86 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0239] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 87 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0240] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 88 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO: 79, SEQ ID NO: 80 or SEQ ID NO: 81.

[0241] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 89 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0242] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 90 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0243] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 91 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0244] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 92 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0245] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 93 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0246] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 94 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0247] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 95 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0248] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 96 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0249] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 97 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0250] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 98 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0251] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 99 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0252] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 100 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0253] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 101 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0254] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 102 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0255] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 103 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0256] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 104 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0257] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 105 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0258] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 106 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0259] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 107 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0260] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 108 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0261] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 109 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0262] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 110 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0263] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 111 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO: 79, SEQ ID NO: 80 or SEQ ID NO: 81.

[0264] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 112 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0265] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 113 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0266] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 114 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0267] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 115 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0268] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 116 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0269] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 117 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0270] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 118 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0271] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 119 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0272] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 120 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0273] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 121 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0274] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 122 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0275] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 123 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0276] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 124 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0277] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 125 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0278] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 126 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0279] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 127 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0280] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 128 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0281] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 129 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0282] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 130 and a light chain variable domain comprising SEQ ID NO: 2, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80 NO:79, SEQ ID NO:80 or SEQ ID NO:81.

[0283] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising: SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, or SEQ ID NO: 145.

[0284] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 131 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0285] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 132 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0286] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 133 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0287] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 134 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0288] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 135 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0289] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 136 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0290] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 137 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0291] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 138 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0292] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 139 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0293] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 140 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0294] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 141 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0295] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 142 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0296] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 143 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0297] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 144 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129 or SEQ ID NO: 130.,

[0298] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 145 and a heavy chain variable domain comprising SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113,SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129 or SEQ ID NO:130. ,

[0299] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of imatinib having one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids substituted with histidine; and a light chain variable domain of imatinib having one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acids substituted with histidine. In some examples of any ABPCs described herein, the heavy chain variable domain of imatinib comprises SEQ ID NO: 146. In some examples of any ABPCs described herein, the light chain variable domain of imatinib comprises SEQ ID NO: 147.

[0300] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NOs: 148-150 are substituted with histidine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 151, SEQ ID NO: 152, and SEQ ID NO: 153, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NOs: 151-153 are substituted with histidine. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NOs: 148-150 are substituted with histidine; and a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 151, SEQ ID NO: 152, and SEQ ID NO: 153, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NOs: 151-153 are substituted with histidine.

[0301] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 146 selected from the group consisting of 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 147 selected from the group consisting of 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97.In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103; and NO: 147. A light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 147 selected from the group consisting of 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97.

[0302] In some examples of any of the ABPCs described herein, the heavy chain variable domain includes a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0303] Table 3. Exemplary combinations of amino acid positions in SEQ ID NO: 146 that can be substituted with histidine

[0304]

[0305]

[0306]

[0307] In some examples of any of the ABPCs described herein, the light chain variable domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 147 listed in Table 4.

[0308] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the heavy chain variable domain is included in SEQ ID NO: 147.

[0309] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain comprises an alanine at position 35 of SEQ ID NO: 147; and a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises an alanine at position 35 of SEQ ID NO: 147. a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in NO: 146 selected from the group consisting of 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103.

[0310] In some examples of any of the ABPCs described herein, the first antigen binding domain includes a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain includes histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97, and wherein the light chain variable domain is included in SEQ ID NO: 147. In some examples of any of the ABPCs described herein, the first antigen binding domain includes: NO:147. A light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:147, wherein the light chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions of SEQ ID NO:147 selected from the group consisting of 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97, and wherein the light chain variable domain comprises an alanine at position 35 of SEQ ID NO:147; and an amino acid sequence identical to SEQ ID NO:147. NO: 146. A heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises a histidine at one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) amino acid positions selected from the group consisting of 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 of SEQ ID NO: 146.

[0311] In some examples of any of the ABPCs described herein, the light chain variable domain comprises a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain comprises a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 147 listed in Table 4 and wherein the light chain variable domain comprises a sequence of SEQ ID NO: 147.

[0312] Table 4. Exemplary combinations of amino acid positions in SEQ ID NO: 147 that can be substituted with histidine

[0313]

[0314]

[0315] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain comprises a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3; and a light chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 147, wherein the light chain variable domain comprises a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 147 listed in Table 4.

[0316] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a light chain variable domain comprising SEQ ID NO: 147, and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes histidine at any specific combination of one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0317] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 25 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0318] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 26 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0319] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 29 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0320] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 32 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0321] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 33 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0322] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 51 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0323] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 91 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0324] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 92 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0325] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 95 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0326] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 96 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0327] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at position 97 in SEQ ID NO: 147; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0328] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes an alanine at position 35 in SEQ ID NO: 2; and a heavy chain variable domain that is at least 90% (e.g., at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at any specific combination of one or more amino acid positions in SEQ ID NO: 146 listed in Table 3.

[0329] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine; and a light chain variable domain of imatinib in which one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty) histidines are substituted with alanine. In some examples of any ABPCs described herein, the heavy chain variable domain of imatinib comprises SEQ ID NO: 146. In some examples of any ABPCs described herein, the light chain variable domain of imatinib comprises SEQ ID NO: 147.

[0330] In some examples of any ABPCs described herein, the first antigen-binding domain comprises a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NOs: 148-150 are substituted with alanine. In some examples of any ABPCs described herein, the first antigen-binding domain comprises a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 151, SEQ ID NO: 152, and SEQ ID NO: 153, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NOs: 151-153 are substituted with alanine. In some examples of any of the ABPCs described herein, the first antigen binding domain comprises: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NOs: 148-150 are substituted with alanine; and a light chain variable domain comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 151, SEQ ID NO: 152, and SEQ ID NO: 153, respectively, wherein a total of one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) histidines in SEQ ID NOs: 151-153 are substituted with alanine.

[0331] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises the heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187 or SEQ ID NO: 188.

[0332] In some examples of any of the ABPCs described herein, the first antigen binding domain includes the light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: NO: 215 or SEQ ID NO: 216.

[0333] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 147 and a heavy chain variable domain comprising SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0334] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 189 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0335] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 190 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0336] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 191 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0337] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 192 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0338] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 193 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0339] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 194 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0340] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 195 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0341] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 196 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0342] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 197 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0343] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 198 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0344] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 199 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0345] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 200 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0346] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 201 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0347] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 202 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0348] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 203 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0349] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 204 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0350] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 205 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0351] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 206 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0352] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 207 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0353] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 208 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0354] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 209 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0355] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 210 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0356] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 211 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0357] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 212 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0358] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 213 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0359] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 214 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0360] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 215 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0361] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 216 and a heavy chain variable domain comprising SEQ ID NO: 146, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 or SEQ ID NO:188.

[0362] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282 or SEQ ID NO: 283.

[0363] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 147 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0364] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 189 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0365] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 190 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0366] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 191 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0367] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 192 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0368] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 193 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0369] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 194 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0370] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 195 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0371] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 196 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0372] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 197 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0373] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 198 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0374] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 199 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0375] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 200 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282 or SEQ ID NO:283.

[0376] In some examples of any of the ABPCs described herein, the first antigen binding domain comprises a light chain variable domain comprising SEQ ID NO: 201 and a heavy chain variable domain comprising SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID ...

Claims

1. A pharmaceutical composition, the pharmaceutical composition comprising an effective amount of an antigen-binding protein construct (ABPC), the antigen-binding protein construct comprising: A first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; Wherein the first antigen-binding domain comprises: (a)(i) A heavy-chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO:1, except that the heavy-chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light-chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light-chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (ii) A heavy-chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, except that the heavy-chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light-chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2; or (iii) A heavy-chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, and a light-chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light-chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (b) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (c) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three complementarity determining regions (CDRs) present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103 and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99 and 101 in SEQ ID NO: 305; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103 and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99 and 101 in SEQ ID NO: 305; or (d) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and comprising three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and comprising three CDRs present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and comprising three CDRs present in SEQ ID NO: 503; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and comprising three CDRs present in SEQ ID NO: 502, and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and comprising three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; and wherein: (a) The dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or (b) The dissociation constant (KD) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the KD at a pH of about 7.0 to about 8.

0.

2. The pharmaceutical composition according to claim 1, wherein the ABPC is degraded in the target mammalian cell after the ABPC is internalized by the target mammalian cell.

3. The pharmaceutical composition according to claim 1 or 2, wherein the ABPC further comprises a conjugated toxin, radioisotope, drug or small molecule.

4. A pharmaceutical composition comprising an effective amount of an antigen-binding protein construct (ABPC), the antigen-binding protein construct comprising: a first antigen-binding domain capable of specifically binding to MET or an epitope of MET presented on the surface of a target mammalian cell; and a conjugated toxin, radioisotope, drug or small molecule, wherein: (a) the first antigen-binding domain comprises: (A)(i) a heavy chain variable domain having at least 90% identity with SEQ ID NO:1 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO:1, except that the heavy chain variable domain comprises histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103 and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity with SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light chain variable domain comprises histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99 and 101 in SEQ ID NO:2; (ii) a heavy chain variable domain having at least 90% identity with SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, except that the heavy chain variable domain comprises histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103 and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity with SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2; or (iii) a heavy chain variable domain having at least 90% identity with SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, and a light chain variable domain having at least 90% identity with SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light chain variable domain comprises histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99 and 101 in SEQ ID NO:2; (B) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100 and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96 and 97 in SEQ ID NO: 147; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100 and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96 and 97 in SEQ ID NO: 147; (C)(i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; or (D) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO:502 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO:502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO:502; and a light chain variable domain having at least 90% identity with SEQ ID NO:503 and comprising three CDRs present in SEQ ID NO:503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO:503; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO:502 and comprising three CDRs present in SEQ ID NO:502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO:502; and a light chain variable domain having at least 90% identity with SEQ ID NO:503 and comprising three CDRs present in SEQ ID NO:503; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO:502 and comprising three CDRs present in SEQ ID NO:502, and a light chain variable domain having at least 90% identity with SEQ ID NO:503 and comprising three CDRs present in SEQ ID NO:503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO:503; (b) The dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or The dissociation constant (KD) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the KD at a pH of about 7.0 to about 8.0; and (c) The composition provides one or more of the following: An increase in toxin release in the target mammalian cells compared to a composition containing the same amount of control ABPC; Increased killing of target mammalian cells as compared to a composition comprising the same amount of control ABPC; and Increased endolysosomal delivery in said target mammalian cells as compared to a composition comprising the same amount of control ABPC.

5. The pharmaceutical composition according to any one of claims 1-4, wherein the first antigen-binding domain comprises: (a) A light chain variable domain selected from: SEQ ID NO:2, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139 or SEQ ID NO:140, and / or A heavy chain variable domain selected from: SEQ ID NO:1, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:94 or SEQ ID NO:111, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO: 2 and the heavy chain variable domain of SEQ ID NO: 1; (ii) the light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain that is not any one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) the heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not any one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140; (b) the following light chain variable domains: SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and / or The following heavy chain variable domains: SEQ ID NO:146, SEQ ID NO:159, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:187, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235 or SEQ ID NO:236, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:147 and the heavy chain variable domain of SEQ ID NO:146; (ii) the light chain variable domain of SEQ ID NO:147 and a heavy chain variable domain that is not any one of SEQ ID NO:159, 164-168, 170, 171, 173, 182-184, 187, 217-228 and 230-236; or (iii) the heavy chain variable domain of SEQ ID NO:146 and a light chain variable domain that is not any one of SEQ ID NO:190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301; (c) The following light chain variable domains: SEQ ID NO:305, SEQ ID NO:352, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:360, SEQ ID NO:362, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:374, SEQ ID NO:378, SEQ ID NO:380, SEQ ID NO:428, SEQ ID NO:429, SEQ ID NO:430, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:438, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:446, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:457, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:470, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:476, SEQ ID NO:479, SEQ ID NO:482, SEQ ID NO:483, SEQ ID NO:485, SEQ ID NO:490, SEQ ID NO:492, SEQ ID NO:494, SEQ ID NO:496 or SEQ ID NO:499, and / or The following heavy chain variable domains: SEQ ID NO:304, SEQ ID NO:313, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:345, SEQ ID NO:347, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399 or SEQ ID NO:400, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:305 and the heavy chain variable domain of SEQ ID NO:304; (ii) the light chain variable domain of SEQ ID NO:305 and a heavy chain variable domain that is not any one of SEQ ID NO:313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393 and 395-400; or (iii) the heavy chain variable domain of SEQ ID NO:304 and a light chain variable domain that is not any one of SEQ ID NO:352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496 and 499; or (d) The following light chain variable domains: SEQ ID NO:503, SEQ ID NO:550, SEQ ID NO:554, SEQ ID NO:556, SEQ ID NO:557, SEQ ID NO:558, SEQ ID NO:559, SEQ ID NO:560, SEQ ID NO:562, SEQ ID NO:565, SEQ ID NO:569, SEQ ID NO:570, SEQ ID NO:571, SEQ ID NO:572, SEQ ID NO:573, SEQ ID NO:574, SEQ ID NO:575, SEQ ID NO:576, SEQ ID NO:697, SEQ ID NO:698, SEQ ID NO:699, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:705, SEQ ID NO:706, SEQ ID NO:707, SEQ ID NO:708, SEQ ID NO:709, SEQ ID NO:710, SEQ ID NO:711, SEQ ID NO:712, SEQ ID NO:713 or SEQ ID NO:732, and / or The following heavy chain variable domains: SEQ ID NO:502, SEQ ID NO:511, SEQ ID NO:513, SEQ ID NO:514, SEQ ID NO:516, SEQ ID NO:517, SEQ ID NO:518, SEQ ID NO:519, SEQ ID NO:520, SEQ ID NO:521, SEQ ID NO:522, SEQ ID NO:523, SEQ ID NO:527, SEQ ID NO:529, SEQ ID NO:538, SEQ ID NO:540, SEQ ID NO:541, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:546, SEQ ID NO:547, SEQ ID NO:578, SEQ ID NO:579, SEQ ID NO:580, SEQ ID NO:581, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:586, SEQ ID NO:587, SEQ ID NO:588, SEQ ID NO:589, SEQ ID NO:590, SEQ ID NO:591, SEQ ID NO:592, SEQ ID NO:593, SEQ ID NO:594, SEQ ID NO:595, SEQ ID NO:596, SEQ ID NO:597, SEQ ID NO:606, SEQ ID NO:621, SEQ ID NO:659 or SEQ ID NO:676, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:503 and the heavy chain variable domain of SEQ ID NO:502; or (ii) the light chain variable domain of SEQ ID NO:503 and a heavy chain variable domain that is not any one of SEQ ID NOs:511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659 and 676; or (iii) the heavy chain variable domain of SEQ ID NO:502 and a light chain variable domain that is not any one of SEQ ID NOs:550, 554, 556-560, 562, 565, 569, 570-576, 697-713 and 732.

6. The pharmaceutical composition according to any one of claims 1-5, wherein the composition provides: an increase in toxin release in the target mammalian cells as compared to a composition comprising the same amount of control ABPC; and / or Increased killing of target mammalian cells as compared to a composition containing the same amount of control ABPC.

7. The pharmaceutical composition according to any one of claims 1-6, wherein the composition provides an increase in endolysosomal delivery in the target mammalian cells as compared to a composition containing the same amount of control ABPC.

8. The pharmaceutical composition according to any one of claims 1-7, wherein the composition: results in less of a decrease in the level of MET presented on the surface of the target mammalian cells as compared to a composition containing the same amount of control ABPC; or does not result in a detectable decrease in the level of MET presented on the surface of the target mammalian cells.

9. The pharmaceutical composition according to any one of claims 1-8, wherein the target mammalian cells are cancer cells.

10. The pharmaceutical composition according to any one of claims 1-9, wherein the ABPC has cytotoxic or cytostatic effects on the target mammalian cells.

11. The pharmaceutical composition according to any one of claims 1-10, wherein the ABPC: has cross-reactivity with non-human primate MET and human MET; or has cross-reactivity with non-human primate MET, human MET, and one or both of rat MET and mouse MET.

12. The pharmaceutical composition according to any one of claims 1-11, wherein the ABPC comprises a single polypeptide.

13. The pharmaceutical composition according to claim 12, wherein the antigen-binding domain is selected from the group consisting of: VH domain, VHH domain, VNAR domain, and scFv.

14. The pharmaceutical composition according to any one of claims 1-11, wherein the ABPC comprises two or more polypeptides.

15. The pharmaceutical composition according to claim 14, wherein the ABPC is an antibody.

16. The pharmaceutical composition according to any one of claims 1-15, wherein the half-life of the ABPC in vivo is decreased as compared to the half-life of control ABPC in vivo.

17. The pharmaceutical composition according to any one of claims 1-16, wherein the ABPC further comprises a second antigen-binding domain.

18. An antigen-binding protein construct (ABPC) comprising: a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell, wherein the first antigen-binding domain comprises: (a) (i) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising the three complementarity-determining regions (CDRs) present in SEQ ID NO:1, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising the three CDRs present in SEQ ID NO:2, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (ii) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising the three CDRs present in SEQ ID NO:1, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising the three CDRs present in SEQ ID NO:2; or (iii) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising the three CDRs present in SEQ ID NO:1, and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising the three CDRs present in SEQ ID NO:2, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (b) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 2 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and comprising three CDRs present in SEQ ID NO: 146, and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and comprising three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (c) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and containing three complementarity-determining regions (CDRs) present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and containing three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and containing three CDRs present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and containing three CDRs present in SEQ ID NO: 305; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and containing three CDRs present in SEQ ID NO: 304, and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and containing three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; or (d) (i) A heavy chain variable domain that has at least 90% identity with SEQ ID NO: 502 and contains three complementarity-determining regions (CDRs) present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain that has at least 90% identity with SEQ ID NO: 503 and contains three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; (ii) A heavy chain variable domain that has at least 90% identity with SEQ ID NO: 502 and contains three CDRs present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain that has at least 90% identity with SEQ ID NO: 503 and contains three CDRs present in SEQ ID NO: 503; or (iii) A heavy chain variable domain that has at least 90% identity with SEQ ID NO: 502 and contains three CDRs present in SEQ ID NO: 502, and a light chain variable domain that has at least 90% identity with SEQ ID NO: 503 and contains three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; and wherein: (a) The dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or (b) The dissociation constant (KD) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the KD at a pH of about 7.0 to about 8.

0.

19. The ABPC according to claim 18, wherein the ABPC is degraded in the target mammalian cell after the ABPC is internalized by the target mammalian cell.

20. The ABPC according to claim 18 or 19, wherein the ABPC further comprises a conjugated toxin, radioisotope, drug, or small molecule.

21. An antigen-binding protein construct (ABPC) comprising: A first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; and A conjugated toxin, radioisotope, drug, or small molecule, wherein: (a) The first antigen-binding domain comprises: (A)(i) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO:1, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (ii) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107 in SEQ ID NO:1; and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2; or (iii) A heavy chain variable domain having at least 90% identity to SEQ ID NO:1 and comprising three CDRs present in SEQ ID NO:1, and a light chain variable domain having at least 90% identity to SEQ ID NO:2 and comprising three CDRs present in SEQ ID NO:2, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101 in SEQ ID NO:2; (B) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and containing three complementarity-determining regions (CDRs) present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 2 and containing three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and containing three CDRs present in SEQ ID NO: 146, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103 in SEQ ID NO: 146; and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and containing three CDRs present in SEQ ID NO: 147; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 146 and containing three CDRs present in SEQ ID NO: 146, and a light chain variable domain having at least 90% identity with SEQ ID NO: 147 and containing three CDRs present in SEQ ID NO: 147, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97 in SEQ ID NO: 147; (C) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three complementarity-determining regions (CDRs) present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105 in SEQ ID NO: 304; and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 304 and comprising three CDRs present in SEQ ID NO: 304, and a light chain variable domain having at least 90% identity with SEQ ID NO: 305 and comprising three CDRs present in SEQ ID NO: 305, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101 in SEQ ID NO: 305; or (D) (i) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and containing three complementarity-determining regions (CDRs) present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and containing three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; (ii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and containing three CDRs present in SEQ ID NO: 502, except that the heavy chain variable domain includes histidine at one or more positions selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107 in SEQ ID NO: 502; and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and containing three CDRs present in SEQ ID NO: 503; or (iii) A heavy chain variable domain having at least 90% identity with SEQ ID NO: 502 and containing three CDRs present in SEQ ID NO: 502, and a light chain variable domain having at least 90% identity with SEQ ID NO: 503 and containing three CDRs present in SEQ ID NO: 503, except that the light chain variable domain includes histidine at one or more positions selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98 in SEQ ID NO: 503; (b) The dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or The dissociation constant (KD) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the KD at a pH of about 7.0 to about 8.0; and (c) The composition provides one or more of the following: An increase in toxin release in the target mammalian cells compared to a composition containing the same amount of control ABPC; Increased killing of target mammalian cells as compared to a composition comprising the same amount of control ABPC; and Increased endolysosomal delivery in said target mammalian cells as compared to a composition comprising the same amount of control ABPC.

22. The ABPC according to any one of claims 18-21, wherein said first antigen-binding domain comprises: (a) a light chain variable domain selected from: SEQ ID NO:2, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139 or SEQ ID NO:140, and / or a heavy chain variable domain selected from: SEQ ID NO:1, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:94 or SEQ ID NO:111, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO: 2 and the heavy chain variable domain of SEQ ID NO: 1; (ii) the light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain that is not any one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) the heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not any one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140; (b) the following light chain variable domains: SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and / or The following heavy chain variable domains: SEQ ID NO:146, SEQ ID NO:159, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:187, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235 or SEQ ID NO:236, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:147 and the heavy chain variable domain of SEQ ID NO:146; (ii) the light chain variable domain of SEQ ID NO:147 and a heavy chain variable domain that is not any one of SEQ ID NO:159, 164-168, 170, 171, 173, 182-184, 187, 217-228 and 230-236; or (iii) the heavy chain variable domain of SEQ ID NO:146 and a light chain variable domain that is not any one of SEQ ID NO:190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301; (c) The following light chain variable domains: SEQ ID NO:305, SEQ ID NO:352, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:360, SEQ ID NO:362, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:374, SEQ ID NO:378, SEQ ID NO:380, SEQ ID NO:428, SEQ ID NO:429, SEQ ID NO:430, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:438, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:446, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:457, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:470, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:476, SEQ ID NO:479, SEQ ID NO:482, SEQ ID NO:483, SEQ ID NO:485, SEQ ID NO:490, SEQ ID NO:492, SEQ ID NO:494, SEQ ID NO:496 or SEQ ID NO:499, and / or The following heavy chain variable domains: SEQ ID NO:304, SEQ ID NO:313, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:345, SEQ ID NO:347, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399 or SEQ ID NO:400, wherein the first antigen binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:305 and the heavy chain variable domain of SEQ ID NO:304; (ii) the light chain variable domain of SEQ ID NO:305 and a heavy chain variable domain that is not any one of SEQ ID NO:313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393 and 395-400; or (iii) the heavy chain variable domain of SEQ ID NO:304 and a light chain variable domain that is not any one of SEQ ID NO:352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496 and 499; or (d) The following light chain variable domains: SEQ ID NO:503, SEQ ID NO:550, SEQ ID NO:554, SEQ ID NO:556, SEQ ID NO:557, SEQ ID NO:558, SEQ ID NO:559, SEQ ID NO:560, SEQ ID NO:562, SEQ ID NO:565, SEQ ID NO:569, SEQ ID NO:570, SEQ ID NO:571, SEQ ID NO:572, SEQ ID NO:573, SEQ ID NO:574, SEQ ID NO:575, SEQ ID NO:576, SEQ ID NO:697, SEQ ID NO:698, SEQ ID NO:699, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:705, SEQ ID NO:706, SEQ ID NO:707, SEQ ID NO:708, SEQ ID NO:709, SEQ ID NO:710, SEQ ID NO:711, SEQ ID NO:712, SEQ ID NO:713 or SEQ ID NO:732, and / or The following heavy chain variable domains: SEQ ID NO:502, SEQ ID NO:511, SEQ ID NO:513, SEQ ID NO:514, SEQ ID NO:516, SEQ ID NO:517, SEQ ID NO:518, SEQ ID NO:519, SEQ ID NO:520, SEQ ID NO:521, SEQ ID NO:522, SEQ ID NO:523, SEQ ID NO:527, SEQ ID NO:529, SEQ ID NO:538, SEQ ID NO:540, SEQ ID NO:541, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:546, SEQ ID NO:547, SEQ ID NO:578, SEQ ID NO:579, SEQ ID NO:580, SEQ ID NO:581, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:586, SEQ ID NO:587, SEQ ID NO:588, SEQ ID NO:589, SEQ ID NO:590, SEQ ID NO:591, SEQ ID NO:592, SEQ ID NO:593, SEQ ID NO:594, SEQ ID NO:595, SEQ ID NO:596, SEQ ID NO:597, SEQ ID NO:606, SEQ ID NO:621, SEQ ID NO:659 or SEQ ID NO:676, wherein the first antigen-binding domain does not comprise (i) the light chain variable domain of SEQ ID NO:503 and the heavy chain variable domain of SEQ ID NO:502; or (ii) the light chain variable domain of SEQ ID NO:503 and a heavy chain variable domain other than any one of SEQ ID NO:511, 513, 514, 516 - 523, 527, 529, 538, 540 - 543, 546, 547, 578 - 597, 606, 621, 659 and 676; or (iii) the heavy chain variable domain of SEQ ID NO:502 and a light chain variable domain other than any one of SEQ ID NO:550, 554, 556 - 560, 562, 565, 569, 570 - 576, 697 - 713 and 732.

23. The ABPC according to any one of claims 18 - 22, wherein the composition provides: an increase in the release of the toxin in the target mammalian cells as compared to a composition comprising the same amount of a control ABPC; and / or Increased killing of target mammalian cells compared to a composition containing the same amount of control ABPC.

24. The ABPC according to any one of claims 18-23, wherein the composition containing the ABPC provides an increase in endolysosomal delivery in the target mammalian cells compared to a composition containing the same amount of control ABPC.

25. The ABPC according to any one of claims 18-24, wherein the composition containing the ABPC: results in less reduction in the level of MET presented on the surface of the target mammalian cells compared to a composition containing the same amount of control ABPC; or does not cause a detectable reduction in the level of MET presented on the surface of the target mammalian cells.

26. The ABPC according to any one of claims 18-25, wherein the target mammalian cells are cancer cells.

27. The ABPC according to any one of claims 18-26, wherein the ABPC has cytotoxic or cytostatic effects on the target mammalian cells.

28. The ABPC according to any one of claims 18-27, wherein the ABPC: has cross-reactivity with non-human primate MET and human MET; or has cross-reactivity with non-human primate MET, human MET, and one or both of rat MET and mouse MET.

29. The ABPC according to any one of claims 18-28, wherein the ABPC comprises a single polypeptide.

30. The ABPC according to claim 29, wherein the antigen-binding domain is selected from the group consisting of VH domain, VHH domain, VNAR domain, and scFv.

31. The ABPC according to any one of claims 18-28, wherein the ABPC comprises two or more polypeptides.

32. The ABPC according to claim 31, wherein the ABPC is an antibody.

33. The ABPC according to any one of claims 18-32, wherein the half-life of the ABPC in vivo is reduced compared to the half-life of control ABPC in vivo.

34. The ABPC according to any one of claims 18-33, wherein the ABPC further comprises a second antigen-binding domain.

35. A kit comprising at least one dose of the pharmaceutical composition according to any one of claims 1-17 or the ABPC according to any one of claims 18-34.

36. Use of the pharmaceutical composition according to any one of claims 1-17 or the ABPC according to any one of claims 18-34 in the manufacture of a medicament for a method of treating cancer characterized by a population of cancer cells having MET or an epitope of MET presented on the surface, the method comprising: administering a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1-17 or the ABPC according to any one of claims 18-34 to a subject identified as having cancer characterized by having said population of cancer cells.

37. Use of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 in the manufacture of a medicament for a method of reducing tumour volume in a subject, wherein the tumour is characterized by a population of cancer cells presenting MET or an epitope of MET on their surface, the method comprising: administering a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 to a subject identified as having cancer, the cancer being characterized by having said population of cancer cells.

38. Use of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 in the manufacture of a medicament for a method of inducing cell death in cancer cells in a subject, wherein MET or an epitope of MET is presented on the surface of the cancer cells, the method comprising: administering a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 to a subject identified as having cancer, the cancer being characterized by having said population of cancer cells.

39. Use of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 in the manufacture of a medicament for a method of reducing the risk of developing metastases or reducing the risk of developing additional metastases in a subject having cancer, wherein the cancer is characterized by a population of cancer cells presenting MET or an epitope of MET on their surface, the method comprising: administering a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1-17 or an ABPC according to any one of claims 18-34 to a subject identified as having cancer, the cancer being characterized by having said population of cancer cells.

Images